

REFINITIV

# DELTA REPORT

## 10-Q

PG - PROCTER & GAMBLE CO

10-Q - DECEMBER 31, 2023 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	1354
CHANGES	189
DELETIONS	785
ADDITIONS	380

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 10-Q

(Mark one)


☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended **September 30, 2023** **December 31, 2023**

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_



**THE PROCTER & GAMBLE COMPANY**  
(Exact name of registrant as specified in its charter)

Ohio

(State of Incorporation)

1-434

(Commission File Number)

31-0411980

(I.R.S. Employer Identification Number)

One Procter & Gamble Plaza, Cincinnati, Ohio

(Address of principal executive offices)

45202

(Zip Code)

(513) 983-1100

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, without Par Value	PG	NYSE
1.125% Notes due 2023	PG23A	NYSE
0.500% Notes due 2024	PG24A	NYSE
0.625% Notes due 2024	PG24B	NYSE
1.375% Notes due 2025	PG25	NYSE
0.110% Notes due 2026	PG26D	NYSE
3.250% EUR Notes due 2026	PG26E	NYSE
4.875% EUR notes due May 2027	PG27A	NYSE
1.200% Notes due 2028	PG28	NYSE
1.250% Notes due 2029	PG29B	NYSE
1.800% Notes due 2029	PG29A	NYSE
6.250% GBP notes due January 2030	PG30	NYSE
0.350% Notes due 2030	PG30C	NYSE
0.230% Notes due 2031	PG31A	NYSE
3.250% EUR Notes due 2031	PG31B	NYSE
5.250% GBP notes due January 2033	PG33	NYSE
1.875% Notes due 2038	PG38	NYSE
0.900% Notes due 2041	PG41	NYSE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☐ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	p	Accelerated filer	..
Non-accelerated filer	..	Smaller reporting company	..
		Emerging growth company	..

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No p

There were 2,356,886,211 2,353,021,054 shares of Common Stock outstanding as of September 30, 2023 December 31, 2023.

FORM 10-Q TABLE OF CONTENTS			Page
<b>PART I</b>	Item 1.	<a href="#">Financial Statements</a>	<a href="#">1</a>
		<a href="#">Consolidated Statements of Earnings</a>	<a href="#">1</a>
		<a href="#">Consolidated Statements of Comprehensive Income</a>	<a href="#">1</a>
		<a href="#">Consolidated Balance Sheets</a>	<a href="#">2</a>
		<a href="#">Consolidated Statements of Shareholders' Equity</a>	<a href="#">3</a>
		<a href="#">Consolidated Statements of Cash Flows</a>	<a href="#">4</a>
		<a href="#">Notes to Consolidated Financial Statements</a>	<a href="#">5</a>
		<a href="#">Note 1: Basis of Presentation</a>	<a href="#">5</a>
		<a href="#">Note 2: New Accounting Pronouncements and Policies</a>	<a href="#">5</a>
		<a href="#">Note 3: Segment Information</a>	<a href="#">5</a>
		<a href="#">Note 4: Goodwill and Intangible Assets</a>	<a href="#">6</a>
		<a href="#">Note 5: Earnings Per Share</a>	<a href="#">8</a>
		<a href="#">Note 6: Share-Based Compensation and Postretirement Benefits</a>	<a href="#">8</a>
		<a href="#">Note 7: Risk Management Activities and Fair Value Measurements</a>	<a href="#">8</a>
		<a href="#">Note 8: Accumulated Other Comprehensive Income/(Loss)</a>	<a href="#">10</a>
		<a href="#">Note 9: Commitments and Contingencies</a>	<a href="#">10</a>
		<a href="#">Note 10: Supplier Supplier Finance Programs</a>	<a href="#">11</a>
		<a href="#">Note 11: Restructuring Program</a>	<a href="#">12</a>
	Item 2.	<a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	<a href="#">11</a>
	Item 3.	<a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	<a href="#">16</a>
	Item 4.	<a href="#">Controls and Procedures</a>	<a href="#">16</a>
<b>PART II</b>	Item 1.	<a href="#">Legal Proceedings</a>	<a href="#">16</a>
	Item 1A.	<a href="#">Risk Factors</a>	<a href="#">16</a>
	Item 2.	<a href="#">Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</a>	<a href="#">16</a>
	Item 5.	<a href="#">Other Information</a>	<a href="#">17</a>
	Item 6.	<a href="#">Exhibits</a>	<a href="#">17</a>
		<a href="#">Signature</a>	<a href="#">17</a>

The Procter & Gamble Company 1

## PART I. FINANCIAL INFORMATION

### Item 1. Financial Statements

#### THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS

Three Months Ended September	Three Months Ended December	Six Months Ended December
30	31	31

(1) Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME								
	Three Months Ended September 30				Three Months Ended December 31		Six Months Ended December 31	
<u>Amounts in millions</u>	<u>Amounts in millions</u>	<u>2023</u>	<u>2022</u>	<u>Amounts in millions</u>	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
NET EARNINGS	NET EARNINGS	\$ 4,556	\$ 3,963	NET EARNINGS	\$ 3,493	\$ 3,959	\$ 8,049	\$ 7,922
OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX	OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX			OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX				
Foreign currency translation	Foreign currency translation	(409)	(712)	Foreign currency translation	492	379	83	(333)

Unrealized losses on investment securities	Unrealized losses on investment securities	(1)	(2)	Unrealized losses on investment securities	(1)	(1)	(2)	(3)
Unrealized gains on defined benefit postretirement plans		45	87					
Unrealized gains/(losses) on defined benefit postretirement plans							Unrealized gains/(losses) on defined benefit postretirement plans	
							(75)	(76) (30) 11
<b>TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX</b>	<b>TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX</b>	<b>(366)</b>	<b>(627)</b>	<b>TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX</b>	<b>416</b>	<b>302</b>	<b>51</b>	<b>(325)</b>
<b>TOTAL COMPREHENSIVE INCOME</b>	<b>TOTAL COMPREHENSIVE INCOME</b>	<b>4,190</b>	<b>3,336</b>	<b>TOTAL COMPREHENSIVE INCOME</b>	<b>3,909</b>	<b>4,261</b>	<b>8,100</b>	<b>7,597</b>
Less: Total comprehensive income attributable to noncontrolling interests	Less: Total comprehensive income attributable to noncontrolling interests	33	19	Less: Total comprehensive income attributable to noncontrolling interests	25	23	58	42
<b>TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER &amp; GAMBLE</b>	<b>TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER &amp; GAMBLE</b>	<b>\$ 4,157</b>	<b>\$ 3,317</b>	<b>TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER &amp; GAMBLE</b>	<b>\$ 3,884</b>	<b>\$ 4,238</b>	<b>\$ 8,041</b>	<b>\$ 7,555</b>

See accompanying Notes to Consolidated Financial Statements.

2 The Procter & Gamble Company

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS

Amounts in millions	Amounts in millions	September 30, 2023	June 30, 2023	Amounts in millions	December 31, 2023	June 30, 2023
<b>Assets</b>	<b>Assets</b>			<b>Assets</b>		
<b>CURRENT ASSETS</b>	<b>CURRENT ASSETS</b>			<b>CURRENT ASSETS</b>		
Cash and cash equivalents	Cash and cash equivalents	\$ 9,733	\$ 8,246	Cash and cash equivalents	\$ 7,890	\$ 8,246
Accounts receivable	Accounts receivable	6,215	5,471	Accounts receivable	6,334	5,471
<b>INVENTORIES</b>	<b>INVENTORIES</b>			<b>INVENTORIES</b>		
Materials and supplies	Materials and supplies	1,759	1,863	Materials and supplies	1,780	1,863
Work in process	Work in process	972	956	Work in process	962	956
Finished goods	Finished goods	4,386	4,254	Finished goods	4,410	4,254
Total inventories	Total inventories	7,117	7,073	Total inventories	7,151	7,073

Prepaid expenses and other current assets	Prepaid expenses and other current assets			1,875	1,858	Prepaid expenses and other current assets			1,736	1,858
<b>TOTAL CURRENT ASSETS</b>	<b>TOTAL CURRENT ASSETS</b>			<b>24,940</b>	<b>22,648</b>	<b>TOTAL CURRENT ASSETS</b>			<b>23,111</b>	<b>22,648</b>
<b>PROPERTY, PLANT AND EQUIPMENT, NET</b>	<b>PROPERTY, PLANT AND EQUIPMENT, NET</b>			<b>21,636</b>	<b>21,909</b>	<b>PROPERTY, PLANT AND EQUIPMENT, NET</b>			<b>22,132</b>	<b>21,909</b>
<b>GOODWILL</b>	<b>GOODWILL</b>			<b>40,239</b>	<b>40,659</b>	<b>GOODWILL</b>			<b>40,916</b>	<b>40,659</b>
<b>TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET</b>	<b>TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET</b>			<b>23,637</b>	<b>23,783</b>	<b>TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET</b>			<b>22,302</b>	<b>23,783</b>
<b>OTHER NONCURRENT ASSETS</b>	<b>OTHER NONCURRENT ASSETS</b>			<b>12,079</b>	<b>11,830</b>	<b>OTHER NONCURRENT ASSETS</b>			<b>12,248</b>	<b>11,830</b>
<b>TOTAL ASSETS</b>	<b>TOTAL ASSETS</b>			<b>\$ 122,531</b>	<b>\$ 120,829</b>	<b>TOTAL ASSETS</b>			<b>\$ 120,709</b>	<b>\$ 120,829</b>
<b>Liabilities and Shareholders' Equity</b>	<b>Liabilities and Shareholders' Equity</b>					<b>Liabilities and Shareholders' Equity</b>				
<b>CURRENT LIABILITIES</b>	<b>CURRENT LIABILITIES</b>					<b>CURRENT LIABILITIES</b>				
Accounts payable	Accounts payable			\$ 14,435	\$ 14,598	Accounts payable			\$ 14,234	\$ 14,598
Accrued and other liabilities	Accrued and other liabilities			10,912	10,929	Accrued and other liabilities			11,100	10,929
Debt due within one year	Debt due within one year			11,811	10,229	Debt due within one year			10,616	10,229
<b>TOTAL CURRENT LIABILITIES</b>	<b>TOTAL CURRENT LIABILITIES</b>			<b>37,158</b>	<b>35,756</b>	<b>TOTAL CURRENT LIABILITIES</b>			<b>35,950</b>	<b>35,756</b>
<b>LONG-TERM DEBT</b>	<b>LONG-TERM DEBT</b>			<b>24,069</b>	<b>24,378</b>	<b>LONG-TERM DEBT</b>			<b>23,096</b>	<b>24,378</b>
<b>DEFERRED INCOME TAXES</b>	<b>DEFERRED INCOME TAXES</b>			<b>6,814</b>	<b>6,478</b>	<b>DEFERRED INCOME TAXES</b>			<b>6,219</b>	<b>6,478</b>
<b>OTHER NONCURRENT LIABILITIES</b>	<b>OTHER NONCURRENT LIABILITIES</b>			<b>6,477</b>	<b>7,152</b>	<b>OTHER NONCURRENT LIABILITIES</b>			<b>6,614</b>	<b>7,152</b>
<b>TOTAL LIABILITIES</b>	<b>TOTAL LIABILITIES</b>			<b>74,517</b>	<b>73,764</b>	<b>TOTAL LIABILITIES</b>			<b>71,880</b>	<b>73,764</b>
<b>SHAREHOLDERS' EQUITY</b>	<b>SHAREHOLDERS' EQUITY</b>					<b>SHAREHOLDERS' EQUITY</b>				
Preferred stock	Preferred stock			812	819	Preferred stock			809	819
Common stock – shares issued –	Common stock – shares issued –	September 2023	4,009.2			Common stock – shares issued –	December 2023	4,009.2		
		June 2023	4,009.2	4,009	4,009		June 2023	4,009.2	4,009	4,009
Additional paid-in capital	Additional paid-in capital			66,822	66,556	Additional paid-in capital			66,935	66,556
Reserve for ESOP debt retirement	Reserve for ESOP debt retirement			(782)	(821)	Reserve for ESOP debt retirement			(782)	(821)
Accumulated other comprehensive loss	Accumulated other comprehensive loss			(12,583)	(12,220)	Accumulated other comprehensive loss			(12,167)	(12,220)
Treasury stock	Treasury stock			(131,029)	(129,736)	Treasury stock			(131,887)	(129,736)
Retained earnings	Retained earnings			120,443	118,170	Retained earnings			121,617	118,170
Noncontrolling interest	Noncontrolling interest			321	288	Noncontrolling interest			294	288

TOTAL SHAREHOLDERS' EQUITY	TOTAL SHAREHOLDERS' EQUITY	48,014	47,065	TOTAL SHAREHOLDERS' EQUITY	48,829	47,065
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 122,531	\$ 120,829	TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 120,709	\$ 120,829

See accompanying Notes to Consolidated Financial Statements.

The Procter & Gamble Company 3

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

		Three Months Ended September 30, 2023											Three Months Ended September 30, 2023			
Dollars in millions;	Dollars in millions;	Common Stock		Reserve		Accumulated		for ESOP		Total		Dollars in millions;	Common Stock		Additional f	
shares in thousands	shares in thousands	Shares	Amount	Preferred Stock	Paid-In Capital	Debt Retirement	Comprehensive Income/(Loss)	Treasury Stock	Retained Earnings	Noncontrolling Interest	Shareholders' Equity	shares in thousands	Shares	Amount	Preferred Stock	Paid-In Capital
BALANCE JUNE 30, 2023		2,362,120	\$4,009	\$819	\$66,556	(\$821)	(\$12,220)	(\$129,736)	\$118,170	\$288	\$47,065					
BALANCE SEPTEMBER 30, 2023												BALANCE SEPTEMBER 30, 2023	2,356,886	\$4,009	\$812	\$66,822
Net earnings	Net earnings								4,521	35	4,556	Net earnings				
Other comprehensive income/(loss)	Other comprehensive income/(loss)						(363)			(2)	(366)	Other comprehensive income/(loss)				
Dividends and dividend equivalents (\$0.9407 per share):	Dividends and dividend equivalents (\$0.9407 per share):											Dividends and dividend equivalents (\$0.9407 per share):				
Common	Common								(2,225)		(2,225)	Common				
Preferred	Preferred								(70)		(70)	Preferred				
Treasury stock purchases	Treasury stock purchases	(9,843)						(1,508)			(1,508)	Treasury stock purchases	(6,879)			
Employee stock plans	Employee stock plans	3,721			265			209			474	Employee stock plans	2,630			113
Preferred stock conversions	Preferred stock conversions	888		(7)	1			6			—	Preferred stock conversions	385		(3)	—
ESOP debt impacts	ESOP debt impacts					39			48		87	ESOP debt impacts				
Noncontrolling interest, net	Noncontrolling interest, net				—					—	—	Noncontrolling interest, net				—
BALANCE SEPTEMBER 30, 2023		2,356,886	\$4,009	\$812	\$66,822	(\$782)	(\$12,583)	(\$131,029)	\$120,443	\$321	\$48,014					
BALANCE DECEMBER 31, 2023												BALANCE DECEMBER 31, 2023	2,353,021	\$4,009	\$809	\$66,935

	Three Months Ended September 30, 2022															
Dollars in millions;	Dollars in millions;	Common Stock		Additional for ESOP		Accumulated Other		Total		Dollars in millions;	Common Stock		Additional for ESOP			
shares in thousands	shares in thousands	Shares	Amount	Preferred Stock	Paid-In Capital	Debt Retirement	Comprehensive Income/(Loss)	Treasury Stock	Retained Earnings	Noncontrolling Interest	Shareholders' Equity	Shares	Amount	Preferred Stock	Paid-In Capital	Retirement

<b>BALANCE JUNE 30, 2022</b>		2,393,877	\$4,009	\$843	\$65,795	(\$916)	(\$12,189)	(\$123,382)	\$112,429	\$265	\$46,854			
<b>BALANCE JUNE 30, 2023</b>												<b>BALANCE JUNE 30, 2023</b>		2,362,120
Net earnings	Net earnings							3,939	24	3,963		Net earnings		\$4,009
Other comprehensive income/(loss)	Other comprehensive income/(loss)					(622)			(5)	(627)		Other comprehensive income/(loss)		\$819
Dividends and dividend equivalents (\$0.9133 per share):														\$66,556
Dividends and dividend equivalents (1.8814 per share):												Dividends and dividend equivalents (1.8814 per share):		
Common	Common							(2,189)		(2,189)		Common		
Preferred	Preferred							(71)		(71)		Preferred		
Treasury stock purchases	Treasury stock purchases	(28,189)					(4,000)			(4,000)		Treasury stock purchases	(16,722)	
Employee stock plans	Employee stock plans	3,011		159			169			328		Employee stock plans	6,351	378
Preferred stock conversions	Preferred stock conversions	998		(9)	1		8			—		Preferred stock conversions	1,273	(10)
ESOP debt impacts	ESOP debt impacts				46			55		101		ESOP debt impacts		1
Noncontrolling interest, net	Noncontrolling interest, net				—				(25)	(25)		Noncontrolling interest, net		—
<b>BALANCE SEPTEMBER 30, 2022</b>		2,369,697	\$4,009	\$834	\$65,955	(\$870)	(\$12,811)	(\$127,205)	\$114,163	\$259	\$44,334			
<b>BALANCE DECEMBER 31, 2023</b>												<b>BALANCE DECEMBER 31, 2023</b>		2,353,021
													\$4,009	\$809
													\$66,935	

See accompanying Notes to Consolidated Financial Statements.

4 The Procter & Gamble Company

#### THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES

Three Months Ended December 31, 2022										
<u>Dollars in millions;</u> <u>shares in thousands</u>	Common Stock		Preferred	Additional	Reserve for	Accumulated Other	Retained	Noncontrolling	Total	
	Shares	Amount	Stock	Paid-In Capital	ESOP Debt Retirement	Comprehensive Income/(Loss)		Interest	Shareholders' Equity	
<b>BALANCE SEPTEMBER 30, 2022</b>	2,369,697	\$4,009	\$834	\$65,955	(\$870)	(\$12,811)	(\$127,205)	\$114,163	\$259	\$44,334
Net earnings								3,933	26	3,959
Other comprehensive income/(loss)						305			(3)	302
Dividends and dividend equivalents (\$0.9133 per share):										
Common								(2,168)		(2,168)
Preferred								(70)		(70)
Treasury stock purchases	(14,426)						(2,002)			(2,002)
Employee stock plans	3,441			189			193			382
Preferred stock conversions	432		(3)	1			2			—
ESOP debt impacts					—			—		—
Noncontrolling interest, net									(12)	(12)
<b>BALANCE DECEMBER 31, 2022</b>	2,359,144	\$4,009	\$831	\$66,145	(\$870)	(\$12,506)	(\$129,012)	\$115,858	\$270	\$44,725



# CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months Ended September 30	
	2023	2022
<b>Amounts in millions</b>		
<b>CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD</b>	<b>\$ 8,246</b>	<b>\$ 7,214</b>
<b>OPERATING ACTIVITIES</b>		
Net earnings	4,556	3,963
Depreciation and amortization	702	663
Share-based compensation expense	125	105
Deferred income taxes	102	(130)
Gain on sale of assets	(3)	(1)
Changes in:		
Accounts receivable	(830)	(740)
Inventories	(142)	(893)
Accounts payable and accrued and other liabilities	857	1,495
Other operating assets and liabilities	(671)	(454)
Other	208	62
<b>TOTAL OPERATING ACTIVITIES</b>	<b>4,904</b>	<b>4,070</b>
<b>INVESTING ACTIVITIES</b>		
Capital expenditures	(925)	(890)
Proceeds from asset sales	3	5
Acquisitions, net of cash acquired	—	(2)
Other investing activity	(300)	55
<b>TOTAL INVESTING ACTIVITIES</b>	<b>(1,222)</b>	<b>(832)</b>
<b>FINANCING ACTIVITIES</b>		
Dividends to shareholders	(2,290)	(2,255)
Additions to short-term debt with original maturities of more than three months	2,179	2,975
Reductions in short-term debt with original maturities of more than three months	(1,906)	(265)
Net additions to other short-term debt	2,172	1,727
Reductions in long-term debt	(1,004)	(1,877)
Treasury stock purchases	(1,500)	(4,000)
Impact of stock options and other	312	188
<b>TOTAL FINANCING ACTIVITIES</b>	<b>(2,038)</b>	<b>(3,507)</b>
<b>EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH</b>	<b>(156)</b>	<b>(235)</b>
<b>CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</b>	<b>1,487</b>	<b>(504)</b>
<b>CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD</b>	<b>\$ 9,733</b>	<b>\$ 6,710</b>

	Six Months Ended December 31, 2022									
	Common Stock		Preferred	Additional	Reserve for	Accumulated Other		Retained	Noncontrolling	Total
<u>Dollars in millions;</u>	Shares	Amount	Stock	Paid-In Capital	ESOP Debt	Comprehensive	Treasury Stock	Earnings	Interest	Shareholders'
<u>shares in thousands</u>					Retirement	Income/(Loss)				Equity
BALANCE JUNE 30, 2022	2,393,877	\$4,009	\$843	\$65,795	(\$916)	(\$12,189)	(\$123,382)	\$112,429	\$265	\$46,854
Net earnings								7,872	50	7,922
Other comprehensive income/(loss)						(317)			(8)	(325)
Dividends and dividend equivalents (1.8266 per share):										
Common								(4,357)		(4,357)
Preferred								(141)		(141)
Treasury stock purchases	(42,615)						(6,002)			(6,002)
Employee stock plans	6,452			348			362			710
Preferred stock conversions	1,430		(12)	2			10			—
ESOP debt impacts					46			55		101

Noncontrolling interest, net		—								(37)	(37)
<b>BALANCE DECEMBER 31, 2022</b>	2,359,144	\$4,009	\$831	\$66,145	(\$870)	(\$12,506)	(\$129,012)	\$115,858	\$270	\$44,725	

See accompanying Notes to Consolidated Financial Statements.

The Procter & Gamble Company 5

## THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES

### CONSOLIDATED STATEMENTS OF CASH FLOWS

Amounts in millions	Six Months Ended December 31	
	2023	2022
<b>CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD</b>	<b>\$ 8,246</b>	<b>\$ 7,214</b>
<b>OPERATING ACTIVITIES</b>		
Net earnings	8,049	7,922
Depreciation and amortization	1,423	1,316
Share-based compensation expense	275	250
Deferred income taxes	(154)	(398)
Gain on sale of assets	(3)	(3)
Indefinite-lived intangible asset impairment charge	1,341	—
Changes in:		
Accounts receivable	(839)	(654)
Inventories	(32)	(655)
Accounts payable and accrued and other liabilities	302	177
Other operating assets and liabilities	(704)	(535)
Other	346	224
<b>TOTAL OPERATING ACTIVITIES</b>	<b>10,004</b>	<b>7,644</b>
<b>INVESTING ACTIVITIES</b>		
Capital expenditures	(1,742)	(1,598)
Proceeds from asset sales	8	8
Acquisitions, net of cash acquired	—	(76)
Other investing activity	(489)	344
<b>TOTAL INVESTING ACTIVITIES</b>	<b>(2,224)</b>	<b>(1,322)</b>
<b>FINANCING ACTIVITIES</b>		
Dividends to shareholders	(4,578)	(4,486)
Additions to short-term debt with original maturities of more than three months	2,798	10,447
Reductions in short-term debt with original maturities of more than three months	(5,862)	(3,260)
Net additions/(reductions) to other short-term debt	3,740	(1,759)
Additions to long-term debt	254	—
Reductions in long-term debt	(2,335)	(1,877)
Treasury stock purchases	(2,503)	(6,002)
Impact of stock options and other	397	437
<b>TOTAL FINANCING ACTIVITIES</b>	<b>(8,087)</b>	<b>(6,500)</b>
<b>EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH</b>	<b>(49)</b>	<b>(182)</b>
<b>CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</b>	<b>(356)</b>	<b>(360)</b>
<b>CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD</b>	<b>\$ 7,890</b>	<b>\$ 6,854</b>

See accompanying Notes to Consolidated Financial Statements.

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The accompanying unaudited Consolidated Financial Statements of The Procter & Gamble Company and subsidiaries ("the Company," "Procter & Gamble," "P&G," "we" or "our") should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2023. We have prepared these statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Note that certain columns and rows may not add due to rounding. In the opinion of management, the accompanying Consolidated Financial Statements contain all normal recurring adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods reported. However, the results of operations included in such financial statements may not necessarily be indicative of annual results.

In September 2022, November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations". 2023-07, "Segment Reporting: Improvements to Reportable Segment Disclosures." This guidance requires disclosure of incremental segment information on an annual and interim disclosures for entities that use supplier finance programs in connection with the purchase of goods and services. basis. This ASU was effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for our fiscal years beginning after December 15, 2023 year ending June 30, 2025 and our interim periods within the fiscal year ending June 30, 2026. We adopted and are currently assessing the impact of this guidance on our disclosures.

In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes: Improvements to Income Tax Disclosures." This guidance requires consistent categories and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment is effective July 1, 2023, except for our fiscal year ending June 30, 2026. We are currently assessing the amendment impact of this guidance on rollforward information, which will be adopted July 1, 2024. See Note 10, Supplier Finance Programs, for the disclosure of our disclosures.

No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on our Consolidated Financial Statements.

Under U.S. GAAP, our operating segments are aggregated into five reportable segments: 1) Beauty, 2) Grooming, 3) Health Care, 4) Fabric & Home Care and 5) Baby, Feminine & Family Care. Our five reportable segments are comprised of:

- *Beauty:* Hair Care (Conditioners, Shampoos, Styling Aids, Treatments); Skin and Personal Care (Antiperspirants and Deodorants, Personal Cleansing, Skin Care);
- *Grooming:* Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Grooming);
- *Health Care:* Oral Care (Toothbrushes, Toothpaste, Other Oral Care); Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory, Vitamins/Minerals/Supplements, Other Personal Health Care);
- *Fabric & Home Care:* Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents); Home Care (Air Care, Dish Care, P&G Professional, Surface Care); and
- *Baby, Feminine & Family Care:* Baby Care (Baby Wipes, Taped Diapers and Pants); Feminine Care (Adult Incontinence, Feminine Care); Family Care (Paper Towels, Tissues, Toilet Paper).

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter &amp; Gamble Company 7

Our operating segments are comprised of similar product categories. Operating segments that individually accounted for 5% or more of consolidated net sales are as follows:

	% of Net sales by operating segment <sup>(1)</sup>					% of Net sales by operating segment <sup>(1)</sup>									
	Three Months Ended September 30					Six Months Ended December 31									
	2023		2022			2023		2022		2023		2022			
Fabric Care	Fabric Care	23	%	23	%	Fabric Care	23	%	23	%	23	%	23	%	
Home Care	Home Care	12	%	12	%	Home Care	12	%	11	%	12	%	11	%	
Skin and Personal Care		10	%	10	%										
Baby Care	Baby Care	9	%	10	%	Baby Care	9	%	10	%	10	%	10	%	
Hair Care	Hair Care	9	%	9	%	Hair Care	9	%	8	%	9	%	9	%	
Skin and Personal Care						Skin and Personal Care									
Family Care	Family Care	8	%	8	%	Family Care	9	%	8	%	8	%	8	%	
Oral Care						Oral Care									
Grooming	Grooming	8	%	8	%	Grooming	8	%	8	%	8	%	8	%	
Oral Care		8	%	8	%										
Personal Health Care						Personal Health Care									

Feminine Care	Feminine Care	7 %	6 %	Feminine Care	6 %	7 %	6 %	7 %
Personal Health Care		6 %	6 %					
Total	Total	100 %	100 %	Total	100 %	100 %	100 %	100 %

(1) % of Net sales by operating segment excludes sales recorded in Corporate.

The following is a summary of reportable segment results:

		Three Months Ended December 31			Six Months Ended December 31		
		Earnings/(Loss)			Earnings/(Loss)		
		Net Sales	Before Income Taxes	Net Earnings/(Loss)	Net Sales	Before Income Taxes	Net Earnings/(Loss)
Beauty	2023	\$ 3,849	\$ 1,112	\$ 868	\$ 7,946	\$ 2,361	\$ 1,839
	2022	3,807	1,145	911	7,768	2,416	1,922
Grooming	2023	1,734	538	440	3,458	1,071	862
	2022	1,643	496	404	3,268	999	808
Health Care	2023	3,172	932	719	6,245	1,821	1,408
	2022	3,051	887	686	5,808	1,687	1,303
Fabric & Home Care	2023	7,415	2,018	1,577	15,061	4,049	3,146
	2022	7,032	1,538	1,171	14,114	3,081	2,343
Baby, Feminine & Family Care	2023	5,146	1,437	1,102	10,332	2,845	2,177
	2022	5,065	1,112	848	9,999	2,167	1,653
Corporate	2023	126	(1,541)	(1,214)	270	(1,849)	(1,383)
	2022	175	(343)	(61)	428	(518)	(107)
Total Company	2023	\$ 21,441	\$ 4,496	\$ 3,493	\$ 43,312	\$ 10,299	\$ 8,049
	2022	20,773	4,835	3,959	41,385	9,832	7,922

#### 4. Goodwill and Intangible Assets

Goodwill is allocated by reportable segment as follows:

	Beauty	Grooming	Health Care	Fabric & Home Care	Baby, Feminine & Family Care	Total Company
Goodwill at June 30, 2023	\$ 13,888	\$ 12,703	\$ 7,718	\$ 1,821	\$ 4,529	\$ 40,659
Acquisitions and divestitures	—	—	—	—	—	—
Translation and other	99	71	56	6	25	257
<b>Goodwill at December 31, 2023</b>	<b>\$ 13,987</b>	<b>\$ 12,774</b>	<b>\$ 7,774</b>	<b>\$ 1,827</b>	<b>\$ 4,554</b>	<b>\$ 40,916</b>

Goodwill increased from June 30, 2023, due to currency translation.

Amounts in millions of dollars except per share amounts or as otherwise specified.

The following is a summary of reportable segment results:

		Three Months Ended September 30		
		Earnings/(Loss)		
		Net Sales	Before Income Taxes	Net Earnings/(Loss)
Beauty	2023	\$ 4,097	\$ 1,249	\$ 971
	2022	3,961	1,271	1,011
Grooming	2023	1,724	533	421
	2022	1,625	503	404
Health Care	2023	3,074	889	689
	2022	2,757	800	617
Fabric & Home Care	2023	7,646	2,031	1,569
	2022	7,082	1,543	1,172
Baby, Feminine & Family Care	2023	5,186	1,408	1,075

Corporate	2022	4,934	1,055	805
	2023	144	(308)	(168)
Total Company	2022	253	(175)	(46)
	2023	\$ 21,871	\$ 5,802	\$ 4,556
	2022	20,612	4,997	3,963

#### 4. Goodwill and Intangible Assets

Goodwill is allocated by reportable segment as follows:

	Beauty	Grooming	Health Care	Fabric & Home Care	Baby, Feminine & Family Care	Total Company
Goodwill at June 30, 2023	\$ 13,888	\$ 12,703	\$ 7,718	\$ 1,821	\$ 4,529	\$ 40,659
Acquisitions and divestitures	—	—	—	—	—	—
Translation and other	(152)	(109)	(100)	(14)	(44)	(420)
<b>Goodwill at September 30, 2023</b>	<b>\$ 13,736</b>	<b>\$ 12,594</b>	<b>\$ 7,618</b>	<b>\$ 1,807</b>	<b>\$ 4,485</b>	<b>\$ 40,239</b>

Goodwill decreased from June 30, 2023, primarily due to currency translation.

Identifiable intangible assets at September 30, 2023 December 31, 2023, were comprised of:

		Gross Carrying Amount	Accumulated Amortization		Gross Carrying Amount	Accumulated Amortization
Intangible assets with determinable lives	Intangible assets with determinable lives	\$ 8,990	\$ (6,308)	Intangible assets with determinable lives	\$ 9,071	\$ (6,444)
Intangible assets with indefinite lives	Intangible assets with indefinite lives	20,955	—	Intangible assets with indefinite lives	19,675	—
<b>Total identifiable intangible assets</b>	<b>Total identifiable intangible assets</b>	<b>\$ 29,945</b>	<b>\$ (6,308)</b>	<b>Total identifiable intangible assets</b>	<b>\$ 28,746</b>	<b>\$ (6,444)</b>

Intangible assets with determinable lives consist of brands, patents, technology and customer relationships. The intangible assets with indefinite lives primarily consist of brands. The amortization expense of determinable-lived intangible assets for the three months ended September 30, 2023 December 31, 2023 and 2022, was \$87 \$84 and \$80, \$79, respectively. For the six months ended December 31, 2023 and 2022, amortization expense was \$171 and \$159, respectively.

Goodwill and indefinite-lived intangible assets are not amortized but are tested at least annually for impairment. We use the income method to estimate the fair value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. When appropriate, the market approach, which leverages comparable company revenue and earnings multiples, is weighted with the income approach to estimate fair value. If the resulting fair value is less than the asset's carrying value, that difference represents an impairment. Our annual impairment testing for goodwill and indefinite-lived intangible assets occurs during the three months ended December 31.

Most of our goodwill reporting units have fair value cushions that significantly exceed their underlying carrying values. The

During the three months ended December 31, 2023, we determined that the fair value of the Gillette indefinite-lived intangible asset is most susceptible was less than its carrying amount. As a result, we recorded a non-cash impairment charge of \$1.3 billion (\$1.0 billion after tax) to future impairment risk. Based on our latest annual impairment testing performed reduce the carrying amount to its estimated fair value during the three months quarter ended December 31, 2022, December 31, 2023. Following the Gillette indefinite-lived intangible asset's fair value exceeded its carrying value by approximately 5%. As of September 30, 2023, impairment charge, the carrying value of the Gillette indefinite-lived intangible asset was \$14.1 billion is \$12.8 billion. We concluded that no triggering event has occurred during The impairment charge arose due to a higher discount rate, weakening of several currencies relative to the quarter ended September 30, 2023. U.S. dollar and the impact of a new restructuring program focused primarily in certain Enterprise Markets, including Argentina and Nigeria.

Adverse changes in the business or in the macroeconomic environment, including foreign currency devaluation, increasing global inflation, market contraction from an economic recession and the Russia-Ukraine War, could reduce the underlying cash flows used to estimate the fair value of the Gillette indefinite-lived intangible asset and trigger a future

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 7

further impairment charge. Further reduction of the Gillette business activities in Russia could reduce the estimated fair value by up to 5% value. The Russia business accounted for approximately 4% of Gillette net sales in the fiscal year ended June 30, 2023.

The most significant assumptions utilized in the determination of the estimated fair value of the Gillette indefinite-lived intangible asset are the net sales growth rates (including residual growth rates), discount rate and royalty rates.

Net sales growth rates could be negatively impacted by reductions or changes in demand for our Gillette products, which may be caused by, among other things: changes in the use and frequency of grooming products, shifts in demand away from one or more of our higher priced products to lower priced products or potential supply chain constraints. In addition, relative global and country/regional macroeconomic factors, including the Russia-Ukraine War, could result in additional and prolonged devaluation of other countries' currencies relative to the U.S. dollar. The residual growth rates represent the expected rate at which the Gillette brand is expected to grow beyond the shorter-term business planning period. The residual growth rates utilized in our fair value estimates are consistent with the brand operating plans and approximate expected long-term category market growth rates. The residual growth rate depends on overall market growth rates, the competitive environment, inflation, relative currency exchange rates and business activities that

impact market share. As a result, the residual growth rate could be adversely impacted by a sustained deceleration in category growth, grooming habit changes, devaluation of currencies against the U.S. dollar or an increased competitive environment.

The discount rate, which is consistent with a weighted average cost of capital that is likely to be expected by a market participant, is based upon industry required rates of return, including consideration of both debt and equity components of the capital structure. Our discount rate may be impacted by adverse changes in the macroeconomic environment, volatility in the equity and debt markets or other country specific factors, such as further devaluation of currencies against the U.S. dollar. Spot rates as of the fair value measurement date are utilized in our fair value estimates for cash flows outside the U.S.

The royalty rate used to determine the estimated fair value for the Gillette indefinite-lived intangible asset is driven by historical and estimated future profitability of the underlying Gillette business. The royalty rate may be impacted by significant adverse changes in long-term operating margins.

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 9

We performed a sensitivity analysis for the Gillette indefinite-lived intangible asset as part of our annual impairment testing during the three months ended **December 31, 2022** **December 31, 2023**, utilizing reasonably possible changes in the assumptions for the discount rate, the short-term and residual growth rates and the royalty **rates** **rate** to demonstrate the potential impacts to estimated fair values. The table below provides, in isolation, the estimated fair value impacts related to a 25 basis-point increase in the discount rate, a 25 basis-point decrease in our short-term and residual growth rates or a 50 basis-point decrease in our royalty **rates**, **rate**, which may result in an **additional** impairment of the Gillette indefinite-lived intangible asset.

	Approximate Percent Change in Estimated Fair Value		
	+25 bps Discount Rate	-25 bps Growth Rates	-50 bps Royalty Rate
Gillette indefinite-lived intangible asset	(6)%	(6)%	(4)%

	Approximate Percent Change in Estimated Fair Value		
	+25 bps Discount Rate	-25 bps Growth Rates	-50 bps Royalty Rate
Gillette indefinite-lived intangible asset	(5)%	(5)%	(4)%

Amounts in millions of dollars except per share amounts or as otherwise specified.

8 The Procter & Gamble Company

## 5. Earnings Per Share

Basic net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble less preferred dividends by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble by the diluted weighted average number of common shares outstanding during the period. The diluted shares include the dilutive effect of stock options and other share-based awards based on the treasury stock method and the assumed conversion of preferred stock.

Net earnings per common share were calculated as follows:

<u>CONSOLIDATED</u>		<u>CONSOLIDATED</u>		<u>CONSOLIDATED</u>		<u>CONSOLIDATED</u>		
<u>AMOUNTS</u>	<u>AMOUNTS</u>	Three Months Ended September 30		<u>AMOUNTS</u>	Three Months Ended December 31		Six Months Ended December 31	
		2023	2022		2023	2022	2023	2022
Net earnings	Net earnings	\$ 4,556	\$ 3,963	Net earnings	\$ 3,493	\$ 3,959	\$ 8,049	\$ 7,922
Less: Net earnings attributable to noncontrolling interests	Less: Net earnings attributable to noncontrolling interests	35	24	Less: Net earnings attributable to noncontrolling interests	25	26	60	50
Net earnings attributable to P&G (Diluted)	Net earnings attributable to P&G (Diluted)	4,521	3,939	Net earnings attributable to P&G (Diluted)	3,468	3,933	7,988	7,872
Less: Preferred dividends	Less: Preferred dividends	70	71	Less: Preferred dividends	70	70	140	141
Net earnings attributable to P&G available to common shareholders (Basic)	Net earnings attributable to P&G available to common shareholders (Basic)	\$ 4,450	\$ 3,868	Net earnings attributable to P&G available to common shareholders (Basic)	\$ 3,398	\$ 3,863	\$ 7,849	\$ 7,731

<u>SHARES IN MILLIONS</u>	<u>SHARES IN MILLIONS</u>			<u>SHARES IN MILLIONS</u>				
Basic weighted average common shares outstanding	Basic weighted average common shares outstanding	2,360.0	2,385.5	Basic weighted average common shares outstanding	2,358.0	2,365.9	2,359.0	2,375.7
Add: Effect of dilutive securities	Add: Effect of dilutive securities			Add: Effect of dilutive securities				
Convertible preferred shares (1)	Convertible preferred shares (1)	74.6	77.4	Convertible preferred shares (1)	73.9	76.7	74.3	77.0
Stock options and other unvested equity awards (2)	Stock options and other unvested equity awards (2)	40.6	40.7	Stock options and other unvested equity awards (2)	36.4	38.6	38.5	39.7
<b>Diluted weighted average common shares outstanding</b>	<b>Diluted weighted average common shares outstanding</b>	<b>2,475.2</b>	<b>2,503.6</b>	<b>Diluted weighted average common shares outstanding</b>	<b>2,468.4</b>	<b>2,481.2</b>	<b>2,471.8</b>	<b>2,492.4</b>
<u>NET EARNINGS PER COMMON SHARE (3)</u>	<u>NET EARNINGS PER COMMON SHARE (3)</u>			<u>NET EARNINGS PER COMMON SHARE (3)</u>				
<b>Basic</b>	<b>Basic</b>	<b>\$ 1.89</b>	<b>\$ 1.62</b>	<b>Basic</b>	<b>\$ 1.44</b>	<b>\$ 1.63</b>	<b>\$ 3.33</b>	<b>\$ 3.25</b>
<b>Diluted</b>	<b>Diluted</b>	<b>\$ 1.83</b>	<b>\$ 1.57</b>	<b>Diluted</b>	<b>\$ 1.40</b>	<b>\$ 1.59</b>	<b>\$ 3.23</b>	<b>\$ 3.16</b>

(1) An overview of preferred shares can be found in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023.

(2) Excludes approximately 1 million 9 million and 18 million 22 million for the three months ended September 30, 2023 December 31, 2023 and 2022, respectively, and 5 million and 19 million for the six months ended December 31, 2023 and 2022, respectively, of weighted average stock options outstanding because the exercise price of these options was greater than their average market value or their effect was antidilutive.

(3) Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.

## 6. Share-Based Compensation and Postretirement Benefits

The following table provides a summary of our share-based compensation expense and postretirement benefit impacts:

		Three Months Ended September 30				Three Months Ended December 31				Six Months Ended December 31	
		2023	2022			2023	2022			2023	2022
Share-based compensation expense	Share-based compensation expense	\$ 125	\$ 105	Share-based compensation expense	\$ 150	\$ 145	\$ 275	\$ 250			
Net periodic benefit cost for pension benefits	Net periodic benefit cost for pension benefits	57	43	Net periodic benefit cost for pension benefits	52	44	109	87			
Net periodic benefit credit for other retiree benefits	Net periodic benefit credit for other retiree benefits	(156)	(132)	Net periodic benefit credit for other retiree benefits	(156)	(132)	(311)	(264)			

Amounts in millions of dollars except per share amounts or as otherwise specified.

## 7. Risk Management Activities and Fair Value Measurements

As a multinational company with diverse product offerings, we are exposed to market risks, such as changes in interest rates, currency exchange rates and commodity prices. There have been no significant changes in our risk management policies or activities during the three six months ended September 30, 2023 December 31, 2023.

The Company has not changed its valuation techniques used in measuring the fair value of any financial assets and liabilities during the period. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers between levels during the periods presented. Also, there was no significant activity within the Level 3 assets and liabilities during the periods presented. There Except for the impairment of the Gillette indefinite-lived intangible asset discussed in Note 4, there were no significant assets or liabilities that were remeasured re-measured at fair value on a non-recurring basis during the periods presented. six months ended December 31, 2023 and 2022.



Cash equivalents were \$8.1 billion \$6.3 billion and \$6.8 billion as of September 30, 2023 December 31, 2023 and June 30, 2023, respectively, and are classified as Level 1 within the fair value hierarchy. The Company had no other material investments in debt or equity securities during the periods presented.

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 9

The fair value of long-term debt was \$25.1 billion \$25.6 billion and \$26.9 billion as of September 30, 2023 December 31, 2023 and June 30, 2023, respectively. This includes the current portion of long-term debt instruments (\$3.0 \$3.4 billion and \$3.9 billion as of September 30, 2023 December 31, 2023 and June 30, 2023, respectively). Certain long-term debt (debt designated as a fair value hedge) is recorded at fair value. All other long-term debt is recorded at amortized cost but is measured at fair value for disclosure purposes. We consider our debt to be Level 2 in the fair value hierarchy. Fair values are generally estimated based on quoted market prices for identical or similar instruments.

#### Disclosures about Financial Instruments

The notional amounts and fair values of financial instruments used in hedging transactions as of September 30, 2023 December 31, 2023 and June 30, 2023, are as follows:

		Notional Amount		Fair Value Asset		Fair Value (Liability)			Notional Amount		Fair Value Asset		Fair Value (Liability)	
		June							June					
		September	June 30,	September	30,	September	June 30,		December	June 30,	December	30,	December	June 30,
		30, 2023	2023	30, 2023	2023	30, 2023	2023		31, 2023	2023	31, 2023	2023	31, 2023	2023
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS														
Interest rate contracts	Interest rate contracts	\$ 2,961	\$ 4,044	\$ —	\$ —	\$ (434)	\$ (445)	Interest rate contracts	\$ 3,098	\$ 4,044	\$ —	\$ —	\$ (317)	\$ (445)
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS														
Foreign currency interest rate contracts	Foreign currency interest rate contracts	\$13,207	\$11,005	\$ 211	\$26	\$ (230)	\$ (631)	Foreign currency interest rate contracts	\$12,267	\$11,005	\$ 5	\$26	\$ (347)	\$ (631)
TOTAL DERIVATIVES DESIGNATED AS HEDGING INSTRUMENTS	TOTAL DERIVATIVES DESIGNATED AS HEDGING INSTRUMENTS	\$16,168	\$15,049	\$ 211	\$26	\$ (664)	\$ (1,076)	TOTAL DERIVATIVES DESIGNATED AS HEDGING INSTRUMENTS	\$15,365	\$15,049	\$ 5	\$26	\$ (664)	\$ (1,076)
														DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts	Foreign currency contracts	\$ 4,310	\$ 3,489	\$ 4	\$ 7	\$ (34)	\$ (42)	Foreign currency contracts	\$ 4,321	\$ 3,489	\$ 37	\$ 7	\$ (7)	\$ (42)
TOTAL DERIVATIVES AT FAIR VALUE	TOTAL DERIVATIVES AT FAIR VALUE	\$20,478	\$18,538	\$ 216	\$33	\$ (698)	\$ (1,118)	TOTAL DERIVATIVES AT FAIR VALUE	\$19,686	\$18,538	\$ 42	\$33	\$ (671)	\$ (1,118)

The fair value of the interest rate derivative asset/(liability) directly offsets the cumulative amount of the fair value hedging adjustment included in the carrying amount of the underlying debt obligation. The carrying amount of the underlying debt obligation, which includes the unamortized discount or premium and the fair value adjustment, was \$2.5 billion \$2.8 billion and \$3.6 billion as of September 30, 2023 December 31, 2023 and June 30, 2023, respectively. In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The carrying value of those debt instruments designated as net investment hedges, which includes the adjustment for the foreign currency transaction gain or loss on those instruments, was \$11.5 billion \$10.8 billion and \$11.8 billion as of September 30, 2023 December 31, 2023 and June 30, 2023, respectively. The increase in the derivative instruments designated as net investment hedges is primarily driven by the Company's decision to leverage favorable interest rate spreads in the foreign currency swap market.

Derivative assets are presented in Prepaid expenses and other current assets or Other noncurrent assets. Derivative liabilities are presented in Accrued and other liabilities or Other noncurrent liabilities. Changes in the fair value of net investment hedges are recognized in the Foreign currency translation component of Other comprehensive income (OCI). All of the Company's derivative assets and liabilities measured at fair value are classified as Level 2 within the fair value hierarchy.

Certain of the Company's financial instruments used in hedging transactions are governed by industry standard netting and collateral agreements with counterparties. If the Company's credit rating were to fall below the levels stipulated in the agreements, the counterparties could demand either collateralization or termination of the arrangements. The aggregate fair value of the instruments covered by these contractual features that are in a net liability position was \$513 \$653 and \$1,088 as of September 30, 2023 December 31, 2023 and June 30, 2023, respectively. The Company has not been required to post collateral as a result of these contractual features.

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 11



Before tax gains on our financial instruments in hedging relationships are categorized as follows:

	Amount of Gain Recognized in OCI on Derivatives		Amount of Loss Recognized in OCI on Derivatives			
	Three Months Ended September 30		Three Months Ended December 31		Six Months Ended December 31	
	2023	2022	2023	2022	2023	2022
<b>DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS</b> <sup>(1)</sup>	<b>DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS</b> <sup>(1) (2)</sup>		<b>DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS</b> <sup>(1) (2)</sup>			
<sup>(2)</sup>						
Foreign exchange contracts	Foreign exchange contracts		Foreign exchange contracts			
	\$		\$		\$	
	285	708	(487)	(1,013)	(202)	(305)

<sup>(1)</sup> For the derivatives in net investment hedging relationships, the amount of gain excluded from effectiveness testing, which was recognized in earnings, was \$67 \$62 and \$46 \$69 for the three months ended September 30, 2023 December 31, 2023 and 2022, respectively. The amount of gain excluded from effectiveness testing was \$130 and \$115 for the six months ended December 31, 2023 and 2022, respectively.

<sup>(2)</sup> In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The amount of gain/(loss) loss recognized in Accumulated other comprehensive income (AOCI) for such instruments was \$344 \$(504) and \$698 \$(862) for the three months ended September 30, 2023 December 31, 2023 and 2022, respectively. The amount of loss recognized in Accumulated other comprehensive income (AOCI) for such instruments was \$(159) and \$(164) for the six months ended December 31, 2023 and 2022, respectively.

Amounts in millions of dollars except per share amounts or as otherwise specified.

10 The Procter & Gamble Company

	Amount of Gain/(Loss) Recognized in Earnings		Amount of Gain/(Loss) Recognized in Earnings			
	Three Months Ended September 30		Three Months Ended December 31		Six Months Ended December 31	
	2023	2022	2023	2022	2023	2022
<b>DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS</b>	<b>DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS</b>		<b>DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS</b>			
Interest rate contracts	Interest rate contracts		Interest rate contracts			
	\$		\$		\$	
	11	(131)	117	(49)	128	(180)
<b>DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS</b>	<b>DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS</b>		<b>DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS</b>			
Foreign currency contracts	Foreign currency contracts		Foreign currency contracts			
	\$		\$		\$	
	(71)	(146)	128	95	57	(51)

The loss gains/(losses) on the derivatives in fair value hedging relationships is fully offset by the mark-to-market impact of the related exposure. These are both recognized in Interest expense. The loss gains/(losses) on derivatives not designated as hedging instruments is substantially offset by the currency mark-to-market of the related exposure. These are both recognized in Selling, general and administrative expense (SG&A).

#### 8. Accumulated Other Comprehensive Income/(Loss)

The table below presents the changes in Accumulated other comprehensive income/(loss) attributable to Procter & Gamble (AOCI), including the reclassifications out of AOCI by component:

	Investment Postretirement Foreign				Investment Postretirement Foreign			
	Securities	Benefit Plans	Currency Translation	Total AOCI	Securities	Benefit Plans	Currency Translation	Total AOCI
Balance at June 30, 2023	Balance at June 30, 2023				Balance at June 30, 2023			
	\$	\$	\$	\$	\$	\$	\$	\$
	13	67	(12,300)	(12,220)	13	67	(12,300)	(12,220)
OCI before reclassifications	OCI before reclassifications				OCI before reclassifications			
<sup>(1)</sup>	(1)	44	(409)	(367)	<sup>(1)</sup>	(2)	(19)	83
								62

Amounts reclassified to the Consolidated Statement of Earnings <sup>(2)</sup>	Amounts reclassified to the Consolidated Statement of Earnings <sup>(2)</sup>					Amounts reclassified to the Consolidated Statement of Earnings <sup>(2)</sup>				
		—	1	—	1		—	(11)	—	(11)
Net current period OCI	Net current period OCI	(1)	45	(409)	(366)	Net current period OCI	(2)	(30)	83	51
Less: OCI attributable to noncontrolling interests	Less: OCI attributable to noncontrolling interests	—	—	(2)	(2)	Less: OCI attributable to noncontrolling interests	—	—	(2)	(2)
<b>Balance at September 30, 2023</b>	<b>\$ 11</b>	<b>\$ 112</b>	<b>\$ (12,707)</b>	<b>\$ (12,583)</b>						
<b>Balance at December 31, 2023</b>						<b>Balance at December 31, 2023</b>	<b>\$ 11</b>	<b>\$ 37</b>	<b>\$ (12,214)</b>	<b>\$ (12,167)</b>

(1) Net of tax (benefit)/expense of \$0, ~~\$22 \$(9)~~ and ~~\$148 \$(85)~~ for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively. Income tax effects within foreign currency translation include impacts from items such as net investment hedge transactions.

(2) Net of tax (benefit)/expense of \$0, ~~\$(2) \$(1)~~ and \$0 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively.

Postretirement benefit plan amounts are reclassified from AOCI into Other non-operating income, net and included in the computation of net periodic postretirement costs.

## 9. Commitments and Contingencies

### Litigation

We are subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust and trade regulation, product liability, advertising, contracts, environmental, patent and trademark matters, labor and employment matters and tax. While considerable uncertainty exists, in the opinion of management and our counsel, the ultimate resolution of the various lawsuits and claims will not materially affect our financial position, results of operations or cash flows.

Amounts in millions of dollars except per share amounts or as otherwise specified.

## 12 The Procter & Gamble Company

We are also subject to contingencies pursuant to environmental laws and regulations that in the future may require us to take action to correct the effects on the environment of prior manufacturing and waste disposal practices. Based on currently available information, we do not believe the ultimate resolution of environmental remediation will materially affect our financial position, results of operations or cash flows.

### Income Tax Uncertainties

The Company is present in approximately 70 countries and over 150 taxable jurisdictions and, at any point in time, has 30–40 jurisdictional audits underway at various stages of completion. We evaluate our tax positions and establish liabilities for uncertain tax positions that may be challenged by local authorities and may not be fully sustained, despite our belief that the underlying tax positions are fully supportable. Uncertain tax positions are reviewed on an ongoing basis and are adjusted in light of changing facts and circumstances, including progress of tax audits, developments in case law and closing of statutes of limitations. Such adjustments are reflected in the tax provision as appropriate. We have tax years open ranging from 2010 and forward. We are generally not able to reliably estimate the timing and ultimate settlement amounts until the close of an audit. **Based on information currently available, we anticipate that over the next 12-month period, audit activity could be completed related to uncertain tax positions in multiple jurisdictions for which we have accrued existing liabilities of approximately \$15, including interest and penalties.**

Additional information on the Commitments and Contingencies of the Company can be found in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023.

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 11

## 10. Supplier Finance Programs

The Company has an ongoing program to negotiate extended payment terms with its suppliers consistent with market practices. The Company also supports a Supply Chain Finance program ("SCF") with several global financial institutions. Under SCF, the Company maintains an accounts payable system to facilitate participating suppliers' ability to sell receivables from the Company to **an** a SCF bank. These participating suppliers negotiate their sales of receivables arrangements directly with the respective SCF bank. The Company is not party to those agreements, but the SCF banks allow the suppliers to utilize the Company's creditworthiness in establishing credit spreads and associated costs. Under this model, this arrangement generally provides the suppliers with more favorable terms than they would be able to secure on their own. The Company has no economic interest in a supplier's decision to sell a receivable. Once a qualifying supplier chooses to participate in SCF, the supplier selects which individual Company invoices to sell to the SCF bank. The Company's obligations to its suppliers, including the amounts due and scheduled payment dates, are not impacted by the supplier's decisions to finance amounts under these arrangements. The Company does not provide any form of guarantee under these financing arrangements. Our payment terms for suppliers under this program generally range from 60 to 180 days. All outstanding amounts related to suppliers participating in SCF are recorded within Accounts payable in our Consolidated Balance Sheets, and the associated payments are included in operating activities within our Consolidated Statements of Cash Flows. The amount due to suppliers participating in SCF and included in Accounts payable was approximately **\$5.6 billion as of December 31, 2023**, **\$5.7 billion as of September 30, 2023** and **June 30, 2023**, and **\$5.8 billion as of June 30, 2022**.

## 11. Restructuring Program

The Company has historically incurred an ongoing annual level of restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization. Before tax costs incurred under the ongoing program have generally ranged from \$250 to \$500 annually. Consistent with our historical policies for restructuring-type activities, the restructuring program charges will be funded by and included within Corporate for management and segment reporting.

In December 2023, the Company announced a limited market portfolio restructuring of its business operations, primarily in certain Enterprise Markets, including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. In connection with this announcement, the Company expects to record incremental restructuring charges of \$1.0 to \$1.5 billion after tax, consisting primarily of foreign currency translation losses to be recognized as non-cash charges upon the substantial liquidation of operations in the affected markets.

For the three months ended December 31, 2023, the Company incurred charges of \$89 including \$48 in Costs of products sold and \$39 in SG&A. For the six months ended December 31, 2023, the Company incurred charges of \$181 including \$109 in Costs of products sold and \$68 in SG&A.

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 13

The following table presents restructuring activity for the six months ended December 31, 2023:

	Separation Costs	Asset-Related Costs	Other Costs	Total
<b>RESERVE JUNE 30, 2023</b>	\$ 155	\$ —	\$ 19	\$ 174
Costs incurred for the three months ended September 30, 2023	69	12	11	92
Costs incurred for the three months ended December 31, 2023	40	30	19	89
Costs incurred for the six months ended December 31, 2023	109	42	30	181
Costs paid/settled for the six months ended December 31, 2023	(91)	(42)	(27)	(160)
<b>RESERVE DECEMBER 31, 2023</b>	<b>\$ 173</b>	<b>\$ —</b>	<b>\$ 22</b>	<b>\$ 195</b>

#### Separation Costs

Employee separation costs relate to severance packages that are primarily voluntary and the amounts calculated are based on salary levels and past service periods.

#### Asset-Related Costs

Asset-related costs consist of both asset write-downs and accelerated depreciation for manufacturing consolidations. Asset write-downs relate to the establishment of a new fair value basis for assets held-for-sale or for disposal. These assets are written down to the lower of their current carrying basis or amounts expected to be realized upon disposal, less minor disposal costs. Charges for accelerated depreciation relate to long-lived assets that will be taken out of service prior to the end of their normal service period.

#### Other Costs

Other restructuring-type charges are incurred as a direct result of the restructuring plan. Such charges include asset removal and termination of contracts related to supply chain and overhead optimization.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

### Forward-Looking Statements

Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may appear throughout this report, including without limitation, the following sections: "Management's Discussion and Analysis," "Risk Factors" and "Notes 4 and 9 to the Consolidated Financial Statements." These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result" and similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events or otherwise, except to the extent required by law.

Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial risks, including foreign currency fluctuations, currency exchange or pricing controls and localized volatility; (2) the ability to successfully manage local, regional or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to effect the expected share repurchases and dividend payments; (3) the ability to manage disruptions in credit markets or to our banking partners or changes to our credit rating; (4) the ability to maintain key manufacturing and supply arrangements (including execution of supply chain optimizations and sole supplier and sole manufacturing plant arrangements) and to manage disruption of business due to various factors, including ones outside of our control, such as natural disasters, acts of war (including the Russia-Ukraine War) or terrorism or disease outbreaks; (5) the ability to successfully manage cost fluctuations and pressures, including prices of commodities and raw materials and costs of labor, transportation, energy, pension and healthcare; (6) the ability to stay on the leading edge of innovation, obtain necessary intellectual property protections and successfully respond to changing consumer habits, evolving digital marketing and selling platform requirements and technological advances attained by, and patents granted to, competitors; (7) the ability to compete with our local and global competitors in new and existing sales channels, including by successfully responding to competitive factors such as prices, promotional incentives and trade terms for products; (8) the ability to manage and maintain key customer relationships; (9) the ability to protect our reputation and brand equity by successfully managing real or perceived issues, including concerns about safety, quality, ingredients, efficacy, packaging content, supply chain practices or similar matters that may arise; (10) the ability to successfully manage the financial, legal, reputational and operational risk associated with third-party relationships, such as our suppliers, contract manufacturers,

Amounts in millions of dollars except per share amounts or as otherwise specified.

distributors, contractors and external business partners; (11) the ability to rely on and maintain key company and third-party information and operational technology systems, networks and services and maintain the security and functionality of such systems, networks and services and the data contained therein; (12) the ability to successfully manage uncertainties related to changing political and geopolitical conditions and potential implications such as exchange rate fluctuations and market contraction; (13) the ability to successfully manage current and expanding regulatory and legal requirements and matters (including, without limitation, those laws and regulations involving product liability, product and packaging composition, intellectual property, labor and employment, antitrust, privacy and data protection, tax, the environment, due diligence, risk oversight, accounting and financial reporting) and to resolve new and pending matters within current estimates; (14) the ability to manage changes in applicable tax laws and regulations; (15) the ability to successfully manage our ongoing acquisition, divestiture and joint venture activities, in each case to achieve the Company's overall business strategy and financial objectives, without impacting the delivery of base business objectives; (16) the ability to successfully achieve productivity improvements and cost savings and manage ongoing organizational changes while successfully identifying, developing and retaining key employees, including in key growth markets where the availability of skilled or experienced employees may be limited; (17) the ability to successfully manage the demand, supply and operational challenges, as well as governmental responses or mandates, associated with a disease outbreak, including epidemics, pandemics or similar widespread public health concerns; (18) the ability to manage the uncertainties, sanctions and economic effects from the war between Russia and Ukraine; and (19) the ability to successfully achieve our ambition of reducing our greenhouse gas emissions and delivering progress towards our environmental sustainability priorities. A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from those projected herein is included in the section titled "Economic Conditions and Uncertainties" and the section titled "Risk Factors" (Part II, Item 1A) of this Form 10-Q.

#### Purpose, Approach and Non-GAAP Measures

The purpose of Management's Discussion and Analysis (MD&A) is to provide an understanding of Procter & Gamble's financial condition, results of operations and cash flows by focusing on changes in certain key measures from year to year. The MD&A is provided as a supplement to, and should be read in conjunction with, our Consolidated Financial Statements and accompanying Notes.

The MD&A is organized in the following sections:

- Overview
- Summary of Results – Three and Six Months Ended September 30, 2023 December 31, 2023
- Economic Conditions and Uncertainties
- Results of Operations – Three and Six Months Ended September 30, 2023 December 31, 2023
- Segment Results – Three and Six Months Ended September 30, 2023 December 31, 2023
- Liquidity and Capital Resources
- Measures Not Defined by U.S. GAAP

Throughout the MD&A we refer to measures used by management to evaluate performance, including unit volume growth, net sales, net earnings, diluted net earnings per common share (diluted EPS) and operating cash flow. We also refer to a number of financial measures that are not defined under U.S. GAAP, consisting of organic sales growth, Core earnings per share (Core EPS), adjusted free cash flow and adjusted free cash flow productivity. The explanation at the end of the MD&A provides the definition of these non-GAAP measures, details on the use and the derivation of these measures, as well as reconciliations to the most directly comparable U.S. GAAP measure.

Management also uses certain market share and market consumption estimates to evaluate performance relative to competition despite some limitations on the availability and comparability of share and consumption information. References to market share and consumption in the MD&A are based on a combination of vendor-purchased traditional brick-and-mortar and online data in key markets as well as internal estimates. All market share references represent the percentage of sales of our products in dollar terms on a constant currency basis relative to all product sales in the category. The Company measures quarter and fiscal year to date market shares through the most recent period for which market share data is available, which typically reflects a lag time of one or two months as compared to the end of the reporting period. Management also uses unit volume growth to evaluate drivers of changes in net sales. Organic volume growth reflects year-over-year changes in unit volume excluding the impacts of acquisitions and divestitures and certain one-time items, if applicable, and is used to explain changes in organic sales. Certain columns and rows may not add due to rounding.

#### OVERVIEW

P&G is a global leader in the fast-moving consumer goods industry, focused on providing branded consumer packaged goods of superior quality and value to our consumers around the world. Our products are sold in approximately 180 countries and territories, primarily through mass merchandisers, e-commerce (including social commerce) channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores (including airport

duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. We also sell direct to individual consumers. We have on-the-ground operations in approximately 70 countries.

Our market environment is highly competitive with global, regional and local competitors. In many of the markets and industry segments in which we sell our products, we compete against other branded products as well as retailers' private-label brands. Additionally, many of the product segments in which we compete are differentiated by price tiers (referred to as super-premium, premium, mid-tier and value-tier products). We believe we are well positioned in the industry segments and markets in which we operate, often holding a leadership or significant market share position.

The table below lists our reportable segments, including the product categories and brand composition within each segment.

Reportable Segments	Product Categories (Sub-Categories)	Major Brands
Beauty	Hair Care (Conditioners, Shampoos, Styling Aids, Treatments)	Head & Shoulders, Herbal Essences, Pantene, Rejoice
	Skin and Personal Care (Antiperspirants and Deodorants, Personal Cleansing, Skin Care)	Olay, Old Spice, Safeguard, Secret, SK-II
Grooming	Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Grooming)	Braun, Gillette, Venus
Health Care	Oral Care (Toothbrushes, Toothpastes, Other Oral Care)	Crest, Oral-B
	Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory, Vitamins/Minerals/Supplements, Other Personal Health Care)	Metamucil, Neurobion, Pepto-Bismol, Vicks
Fabric & Home Care	Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents)	Ariel, Downy, Gain, Tide
	Home Care (Air Care, Dish Care, P&G Professional, Surface Care)	Cascade, Dawn, Fairy, Febreze, Mr. Clean, Swiffer
Baby, Feminine & Family Care	Baby Care (Baby Wipes, Taped Diapers and Pants)	Luvs, Pampers
	Feminine Care (Adult Incontinence, Feminine Care)	Always, Always Discreet, Tampax
	Family Care (Paper Towels, Tissues, Toilet Paper)	Bounty, Charmin, Puffs

Throughout the MD&A, we reference business results by region, which are comprised of North America, Europe, Greater China, Latin America, Asia Pacific and India, Middle East and Africa (IMEA).

The following table provides the percentage of net sales and net earnings by reportable business segment (excluding Corporate) for the three and six months ended September 30, 2023 December 31, 2023:

	Three Months Ended September 30, 2023					Three Months Ended December 31, 2023					Six Months Ended December 31, 2023				
		Net Sales		Net Earnings			Net Sales		Net Earnings			Net Sales		Net Earnings	
Beauty	Beauty	19	%	20	%	Beauty	18	%	19	%		18	%	20	%
Grooming	Grooming	8	%	9	%	Grooming	8	%	9	%		8	%	9	%
Health Care	Health Care	14	%	15	%	Health Care	15	%	15	%		15	%	15	%
Fabric & Home Care	Fabric & Home Care	35	%	33	%	Fabric & Home Care	35	%	34	%		35	%	33	%
Baby, Feminine & Family Care	Baby, Feminine & Family Care	24	%	23	%	Baby, Feminine & Family Care	24	%	23	%		24	%	23	%
Total Company	Total Company	100	%	100	%	Total Company	100	%	100	%		100	%	100	%

## RECENT DEVELOPMENTS

### Limited Market Portfolio Restructuring

In December 2023, the Company announced a limited market portfolio restructuring of its business operations, primarily in certain Enterprise Markets, including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. In connection with this announcement, the Company expects to record incremental restructuring charges of \$1.0 to \$1.5 billion after tax, consisting primarily of foreign currency translation losses to be recognized as non-cash charges upon the substantial liquidation of operations in the affected markets.

Although the timing of the completion of this restructuring program has yet to be determined, the Company currently anticipates that these restructuring charges will be recognized in the fiscal years ending June 30, 2024 and 2025. Consistent with our historical policies for ongoing restructuring-type activities, resulting charges will be funded by and included within Corporate for segment reporting. Restructuring charges above the normal ongoing level of restructuring costs will be reported as non-core charges. For more details on the restructuring program, refer to Note 11 to the Consolidated Financial Statements.

16 The Procter & Gamble Company

### Intangible Asset Impairment

During the three months ended December 31, 2023, the Company recorded a \$1.3 billion before tax (\$1.0 billion after tax) non-cash impairment charge, on intangible assets acquired as part of the Company's 2005 acquisition of The Gillette Company.

The impairment charge arose from a reduction in the estimated fair value of the Gillette indefinite-lived intangible asset due to a higher discount rate, weakening of several currencies relative to the U.S. dollar and the impact of the non-core restructuring program described above. This impairment charge adjusted the carrying value of the Gillette indefinite-lived intangible asset to fair value. For a more detailed discussion of the Gillette impairment, refer to Note 4 to the Consolidated Financial Statements.

### SUMMARY OF RESULTS – Three Six Months Ended September 30, 2023 December 31, 2023

The following are highlights of results for the **three six** months ended **September 30, 2023** **December 31, 2023**, versus the **three six** months ended **September 30, 2022** **December 31, 2022**:

- Net sales increased **6%** **5%** to **\$21.9 billion** **\$43.3 billion** versus the prior year period. Net sales increased **double high single** digits in Health Care **high single digits in** and Fabric & Home Care, mid-single digits in Grooming and **low single digits in** Baby, Feminine & Family Care and **low single digits in** Beauty. Organic sales, which exclude the impacts of acquisitions and divestitures and foreign exchange, **also increased 7%** **5%**. Organic sales increased **double high single digits in** Grooming and Fabric & Home Care, mid-single digits in Health Care **high single digits in** Fabric & Home Care, Grooming and Baby, Feminine & Family Care and **mid-single low single** digits in Beauty.
- Net earnings were **\$4.6 billion** **\$8.0 billion**, an increase of **\$593 million** **\$127 million**, or **15%** **2%**, versus the prior year period due to the increase in net sales, **and an increase in operating margin**, partially offset by the non-cash impairment charge of \$1.0 billion after taxes related to the Gillette intangible asset.
- Net earnings attributable to Procter & Gamble were **\$4.5 billion**, **\$8.0 billion**, an increase of **\$582 million** **\$116 million**, or **15%** **1%**, versus the prior year period.
- Diluted EPS increased **17%** **2%** to **\$1.83** **\$3.23** due to the increase in net earnings. Core EPS, which excludes the charge for the Gillette intangible asset impairment and **a reduction in the weighted average shares outstanding**, incremental restructuring, increased 16% to \$3.66.
- Operating cash flow was **\$4.9 billion** **\$10.0 billion**. Adjusted free cash flow, which is defined as operating cash flow less capital expenditures and excluding payments for the transitional tax **payments** resulting from the U.S. Tax Act, was **\$4.4 billion** **\$8.7 billion**. Adjusted free cash flow productivity, which is defined as adjusted free cash flow as a percentage of net earnings **excluding the Gillette intangible asset impairment charge**, was **97%** **96%**.

## **ECONOMIC CONDITIONS AND UNCERTAINTIES**

**Global Economic Conditions.** Our products are sold in numerous countries across North America, Europe, Latin America, Asia, Australia and Africa, with more than half our sales generated outside the United States. Our largest international markets are Greater China, the United Kingdom, Canada, Japan and Germany and collectively comprised more than 20% of our net sales in the fiscal year 2023. As such, we are exposed to and impacted by global macroeconomic factors, geopolitical tensions, U.S. and foreign government policies and foreign exchange fluctuations. We are also exposed to market risks from operating in challenging environments including unstable economic, political and social conditions, civil unrest, military conflicts, natural disasters, debt and credit issues and currency controls or fluctuations. These risks can reduce our net sales or erode our operating margins and consequently reduce our net earnings and cash flows.

**Changes in Costs.** Our costs are subject to fluctuations, particularly due to changes in commodity and input material prices, transportation costs, other broader inflationary impacts and our own productivity efforts. We have significant exposures to certain commodities and input materials, in particular certain oil-derived materials like resins and paper-based materials like pulp. Volatility in the market price of these commodities and input materials has a direct impact on our costs. Disruptions in our manufacturing, supply and distribution operations due to energy shortages, natural disasters, labor or freight constraints could also lead to increased costs. New or increased legal or regulatory requirements, along with initiatives to meet our sustainability goals, could also result in increased costs due to higher material costs and investments in facilities and equipment. We strive to implement, achieve and sustain cost improvement plans, including supply chain optimization and general overhead and workforce optimization. Increased pricing in response to certain inflationary or cost increases may also offset portions of the cost impacts; however, such price increases may impact product consumption. If we are unable to manage cost impacts through pricing actions and consistent productivity improvements, it may adversely impact our net sales, gross margin, operating margin, net earnings and cash flows.

**Foreign Exchange.** We have significant translation and transaction exposure to the fluctuation of exchange rates. Translation exposures relate to exchange rate impacts of measuring income statements of foreign subsidiaries that do not use the U.S. dollar as their functional currency. Transaction exposures relate to 1) the impact from input costs that are denominated in a currency other than the local reporting currency and 2) the revaluation of transaction-related working capital balances denominated in currencies other than the functional currency. In the past three years, weakening of certain foreign currencies versus the U.S. dollar has resulted in significant foreign exchange impacts leading to lower net sales, net earnings and cash flows. **Certain countries that recently had and are currently experiencing significant exchange rate fluctuations include Argentina, Brazil, Japan, Russia, Turkey and the United Kingdom.** These fluctuations have significantly impacted our historical net sales, net earnings and cash flows and could do so in the future. **Certain countries that are currently experiencing significant exchange rate fluctuations include Argentina, Russia and Turkey.** Increased pricing in response to certain fluctuations in foreign currency exchange rates may offset portions of the currency

The Procter & Gamble Company 17

impacts but could also have a negative impact on the consumption of our products, which would negatively affect our net sales, gross margin, operating margin, net earnings and cash flows.

**Government Policies.** Our net sales, gross margin, operating margin, net earnings and cash flows could be affected by changes in U.S. or foreign government legislative, regulatory or enforcement policies. For example, our net earnings and cash flows could be affected by any future legislative or regulatory changes in U.S. or non-U.S. tax policy, including changes resulting from the current work being led by the OECD/G20 Inclusive Framework focused on "Addressing the Challenges of the Digitalization of the Economy." The breadth of the OECD project extends beyond pure digital businesses and **as proposed**, is likely to impact most large multinational businesses by both redefining jurisdictional taxation rights and establishing a 15% global minimum tax. Our net sales, gross margin, operating margin, net earnings and cash flows may also be impacted by changes in U.S. and foreign government policies related to environmental and climate change matters. Additionally, we attempt to carefully manage our debt, currency and other exposures in certain countries with currency exchange, import authorization and pricing controls, such as Argentina, Egypt and Pakistan. Further, our net sales, gross margin, operating margin, net earnings and cash flows could be affected by changes to international trade agreements in North America and elsewhere. Changes in government policies in the above areas might cause an increase or decrease in our net sales, gross margin, operating margin, net earnings and cash flows.

**Russia-Ukraine War.** The war between Russia and Ukraine has negatively impacted our operations. Our Ukraine business includes two manufacturing sites and accounted for less than 1% of consolidated net sales and consolidated net earnings in the fiscal year ended June 30, 2023. Net assets of our Ukraine business accounted for less than 1% of consolidated net assets as of **September 30, 2023** **December 31, 2023**. Our Russia business includes two manufacturing sites. Beginning in March 2022, the Company reduced its product portfolio, discontinued new capital investments and suspended media, advertising and promotional activity in Russia. The Russia business accounted for approximately 2%



of consolidated net sales and consolidated net earnings in the fiscal year ended June 30, 2023. Net assets of our Russia business accounted for less than 2% of consolidated net assets as of **September 30, 2023** **December 31, 2023**.

Future impacts to the Company are difficult to predict due to the high level of uncertainty related to the war's duration, evolution and ultimate resolution. Within Ukraine, there is a possibility of physical damage and destruction of our two manufacturing facilities. We may not be able to operate our manufacturing sites and source raw materials from our suppliers or ship finished products to our customers.

Within Russia, we may not be able to continue our reduced operations at current levels due to sanctions and counter-sanctions, monetary, currency or payment controls, legislative restrictions or policies, restrictions on access to financial institutions and supply and transportation challenges. Our suppliers, distributors and retail customers are also impacted by the war and their ability to successfully maintain their operations could also impact our operations or negatively impact the sales of our products.

More broadly, there could be additional negative impacts to our net sales, earnings and cash flows should the situation escalate beyond its current scope, including, among other potential impacts, economic recessions in certain neighboring countries or globally due to inflationary pressures and supply chain cost increases or the geographic proximity of the war relative to the rest of Europe.

For additional information on risk factors that could impact our business results, please refer to Risk Factors in Part I, Item 1A of the Company's Form 10-K for the fiscal year ended June 30, 2023.

18 The Procter & Gamble Company

## RESULTS OF OPERATIONS – Three Months Ended **September 30, 2023** **December 31, 2023**

The following discussion provides a review of results for the three months ended **September 30, 2023** **December 31, 2023**, versus the three months ended **September 30, 2022** **December 31, 2022**.

Amounts in millions, except per share amounts	Amounts in millions, except per share amounts	Three Months Ended September 30			Amounts in millions, except per share amounts	Three Months Ended December 31		
		2023	2022	% Chg		2023	2022	% Chg
Net sales	Net sales	\$ 21,871	\$ 20,612	6%	Net sales	\$ 21,441	\$ 20,773	3%
Operating income	Operating income	5,767	4,939	17%	Operating income	4,433	4,785	(7)%
Earnings before income taxes	Earnings before income taxes	5,802	4,997	16%	Earnings before income taxes	4,496	4,835	(7)%
Net earnings	Net earnings	4,556	3,963	15%	Net earnings	3,493	3,959	(12)%
Net earnings attributable to Procter & Gamble	Net earnings attributable to Procter & Gamble	4,521	3,939	15%	Net earnings attributable to Procter & Gamble	3,468	3,933	(12)%
Diluted net earnings per common share	Diluted net earnings per common share	1.83	1.57	17%	Diluted net earnings per common share	1.40	1.59	(12)%
Core net earnings per common share					Core net earnings per common share	1.84	1.59	16%
COMPARISONS AS A PERCENTAGE OF NET SALES	COMPARISONS AS A PERCENTAGE OF NET SALES	Three Months Ended September 30			COMPARISONS AS A PERCENTAGE OF NET SALES	Three Months Ended December 31		
		2023	2022	Basis Pt Chg		2023	2022	Basis Pt Chg
Gross margin	Gross margin	52.0 %	47.4 %	460	Gross margin	52.7 %	47.5 %	520
Selling, general & administrative expense	Selling, general & administrative expense	25.6 %	23.4 %	220	Selling, general & administrative expense	25.8 %	24.5 %	130
Operating income	Operating income	26.4 %	24.0 %	240	Operating income	20.7 %	23.0 %	(230)
Earnings before income taxes	Earnings before income taxes	26.5 %	24.2 %	230	Earnings before income taxes	21.0 %	23.3 %	(230)
Net earnings	Net earnings	20.8 %	19.2 %	160	Net earnings	16.3 %	19.1 %	(280)

Net earnings attributable to Procter & Gamble	Net earnings attributable to Procter & Gamble	20.7	%	19.1	%	160	Net earnings attributable to Procter & Gamble	16.2	%	18.9	%	(270)
---	---	------	---	------	---	-----	---	------	---	------	---	-------

#### Net Sales

Net sales for the quarter increased 6% 3% to \$21.9 billion \$21.4 billion. The increase in net sales was due to higher pricing of 7% and favorable mix of 1% 4%, partially offset by unfavorable foreign exchange of 1%. Unit volume and a decrease in unit volume of 1% mix were unchanged. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 7%. Favorable mix was primarily driven 4% while organic volume declined by volume growth in North America, which has higher than Company-average selling prices. 1%.

The following table summarizes key drivers of the change in net sales by reportable segment:

	Net Sales Change Drivers 2023 vs. 2022 (Three Months Ended September 30) <sup>(1)</sup>										Net Sales Change Drivers 2023 vs. 2022 (Three Months Ended December 31) <sup>(1)</sup>																			
		Volume with Acquisitions & Divestitures		Volume Excluding Acquisitions & Divestitures		Foreign Exchange		Price	Mix	Other <sup>(2)</sup>	Net Sales Growth			Volume with Acquisitions & Divestitures		Volume Excluding Acquisitions & Divestitures		Foreign Exchange		Price	Mix	Other <sup>(2)</sup>	Net Sales Growth							
Beauty	Beauty	—	%	—	%	(3)	%	7	%	(2)	%	1	%	3	%	Beauty	—	%	(1)	%	(1)	%	4	%	(3)	%	1	%		
Grooming	Grooming	(2)	%	(2)	%	(3)	%	9	%	1	%	1	%	6	%	Grooming	1	%	1	%	(3)	%	7	%	1	%	—	%	6	%
Health Care	Health Care	2	%	2	%	1	%	6	%	2	%	—	%	11	%	Health Care	(3)	%	(4)	%	2	%	5	%	1	%	(1)	%	4	%
Fabric & Home Care	Fabric & Home Care	(1)	%	—	%	(1)	%	8	%	1	%	1	%	8	%	Fabric & Home Care	—	%	1	%	—	%	4	%	1	%	—	%	5	%
Baby, Feminine & Family Care	Baby, Feminine & Family Care	(3)	%	(3)	%	(2)	%	8	%	2	%	—	%	5	%	Baby, Feminine & Family Care	(2)	%	(2)	%	(1)	%	4	%	1	%	—	%	2	%
Total Company	Total Company	(1)	%	(1)	%	(1)	%	7	%	1	%	—	%	6	%	Total Company	—	%	(1)	%	(1)	%	4	%	—	%	—	%	3	%

<sup>(1)</sup> Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.

<sup>(2)</sup> Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.

#### Operating Costs

Gross margin increased 460 520 basis points to 52.0% 52.7% of net sales for the quarter. The increase in gross margin was due to:

- a 330 basis-point increase due to higher pricing, 240 basis points of manufacturing productivity savings,
- 160 200 basis points of lower commodity costs and
- 150 a 190 basis-point increase due to higher pricing.

These impacts were partially offset by:

- a 70 basis-point decline from unfavorable foreign exchange impacts,
- 20 basis points of product and packaging investments and
- 20 basis points of rounding and other impacts.

The Procter & Gamble Company 19

Total SG&A spending increased 8% to \$5.5 billion versus the prior year period due to increased marketing spending and overhead costs. SG&A as a percentage of net sales increased 130 basis points to 25.8% due to the increase in marketing spending as a percentage of sales. Marketing spending as a percentage of net sales increased 140 basis points as the increase in marketing spending was partially offset by the positive scale impacts of the net sales increase and productivity savings. Overhead costs as a percentage of net sales were unchanged as wage inflation, foreign exchange and other cost increases were offset by the positive scale impacts of the net sales increase and productivity savings. Productivity-driven cost savings delivered 100 basis points of benefit to SG&A as a percentage of net sales.

The Company recorded a non-cash impairment charge of \$1.3 billion (\$1.0 billion after tax) on the Gillette intangible asset. The impairment charge arose from a reduction in the estimated fair value of the Gillette indefinite-lived intangible asset due to a higher discount rate, weakening of several currencies relative to the U.S. dollar and the impact of the limited market portfolio restructuring program focused primarily in certain Enterprise Markets, including Argentina and Nigeria. For further discussion of the Gillette impairment charge, refer to Note 4 to the Consolidated Financial Statements.

#### Non-Operating Expenses and Income



Interest expense was \$248 million for the quarter, an increase of \$77 million versus the prior year period due primarily to higher interest rates. Interest income was \$133 million for the quarter, an increase of \$67 million versus the prior year period due primarily to higher interest rates. Other non-operating income was \$177 million, which is an increase of \$22 million versus the prior year period.

#### Income Taxes

The effective income tax rate for the three months ended December 31, 2023, was 22.3%, compared to 18.1% for the three months ended December 31, 2022. The increase in the effective tax rate was primarily driven by 180 basis points due to the net impact of the prior year recognition of operating loss carryforwards and 180 basis points due to unfavorable geographic mix impacts.

#### Net Earnings

Operating income decreased \$352 million, or 7%, to \$4.4 billion for the quarter, due to the non-cash, before tax impairment charge to the Gillette intangible asset of \$1.3 billion and an increase in SG&A spending as a percentage of net sales. This was partially offset by the increase in net sales, along with the increase in gross margin, all of which are discussed above.

Net earnings decreased \$466 million, or 12%, to \$3.5 billion due to the decrease in operating income and an increase in the effective tax rate. Foreign exchange had a negative impact of approximately \$78 million on net earnings for the quarter, including both transactional and translational impacts from converting earnings from foreign subsidiaries to U.S. dollars. Net earnings attributable to Procter & Gamble decreased \$465 million, or 12%, to \$3.5 billion for the quarter. Diluted EPS decreased 12% to \$1.40 versus the prior year period due to the decrease in net earnings. Core EPS, which represents diluted EPS excluding charges for the Gillette intangible asset impairment and incremental restructuring, increased 16% to \$1.84.

#### RESULTS OF OPERATIONS – Six Months Ended December 31, 2023

The following discussion provides a review of results for the six months ended December 31, 2023, versus the six months ended December 31, 2022.

Amounts in millions, except per share amounts	Six Months Ended December 31		
	2023	2022	% Chg
Net sales	\$ 43,312	\$ 41,385	5%
Operating income	10,200	9,724	5%
Earnings before income taxes	10,299	9,832	5%
Net earnings	8,049	7,922	2%
Net earnings attributable to Procter & Gamble	7,988	7,872	1%
Diluted net earnings per common share	3.23	3.16	2%
Core net earnings per common share	3.66	3.16	16%

20 The Procter & Gamble Company

COMPARISONS AS A PERCENTAGE OF NET SALES	Six Months Ended December 31		
	2023	2022	Basis Pt Chg
Gross margin	52.3 %	47.5 %	480
Selling, general & administrative expense	25.7 %	24.0 %	170
Operating income	23.6 %	23.5 %	10
Earnings before income taxes	23.8 %	23.8 %	—
Net earnings	18.6 %	19.1 %	(50)
Net earnings attributable to Procter & Gamble	18.4 %	19.0 %	(60)

#### Net Sales

Net sales for the period increased 5% to \$43.3 billion. The increase in net sales was due to higher pricing of 6%, partially offset by unfavorable foreign exchange of 1% and a 1% decrease in unit volume. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales also increased 5%.

The following table summarizes key drivers of the change in net sales by reportable segment:

Net Sales Change Drivers 2023 vs. 2022 (Six Months Ended December 31) <sup>(1)</sup>								
	Volume with Acquisitions & Divestitures	Volume Excluding Acquisitions & Divestitures	Foreign Exchange	Price	Mix	Other <sup>(2)</sup>	Net Sales Growth	
Beauty	— %	— %	(2)%	5 %	(2)%	1 %	2 %	
Grooming	(1)%	(1)%	(3)%	8 %	1 %	1 %	6 %	
Health Care	(1)%	(1)%	2 %	5 %	2 %	— %	8 %	
Fabric & Home Care	— %	— %	(1)%	6 %	1 %	1 %	7 %	
Baby, Feminine & Family Care	(2)%	(3)%	(1)%	6 %	1 %	(1)%	3 %	

Total Company	(1)%	(1)%	(1)%	6 %	— %	1 %	5 %
---------------	------	------	------	-----	-----	-----	-----

(1) Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.

(2) Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.

### Operating Costs

Gross margin increased 480 basis points to 52.3% of net sales for the period. The increase in gross margin was due to:

- a 250 basis-point increase due to higher pricing,
- 180 basis points of lower commodity costs and
- 180 basis points of manufacturing productivity savings.

These impacts were partially offset by

- a 60 basis-point decline from unfavorable product mix including the disproportionate decline of the super-premium SK-II brand, by:
- a 60 basis-point decline from unfavorable foreign exchange impacts,
- a 30 basis-point decline from unfavorable product mix including the decline of the super-premium SK-II brand,
- 30 basis points of product and packaging investments and
- a 30 basis-point 10 basis points of decline from other loss of manufacturing costs, scale benefits.

Total SG&A spending increased 16% 12% to \$5.6 billion \$11.1 billion versus the prior year period due to increased marketing spending, overhead costs and other operating costs. SG&A as a percentage of net sales increased 220 170 basis points to 25.6% 25.7% due to the increase in marketing spending, overhead spending and other operating costs as a percentage of sales. Marketing spending as a percentage of net sales increased 130 140 basis points as the increase in marketing spending was partially offset by the positive scale impacts of the net sales increase and productivity savings. Overhead costs as a percentage of net sales increased 40 20 basis points due to wage inflation and other cost increases, partially offset by the positive scale impacts of the net sales increase and productivity savings. Other operating expenses as a percentage of net sales increased 50 20 basis points due to higher foreign exchange transactional charges, points. Productivity-driven cost savings delivered 60 80 basis points of benefit to SG&A as a percentage of net sales.

The Company recorded a non-cash impairment charge of \$1.3 billion (\$1.0 billion after tax) on the Gillette intangible asset. The impairment charge arose from a reduction in the estimated fair value of the Gillette indefinite-lived intangible asset due to a higher discount rate, weakening of several currencies relative to the U.S. dollar and the impact of the limited market portfolio restructuring program. For further discussion of the Gillette impairment charge, refer to Note 4 to the Consolidated Financial Statements.

The Procter & Gamble Company 21

### Non-Operating Expenses and Income

Interest expense was \$225 million \$472 million for the quarter, period, an increase of \$102 million \$178 million versus the prior year period due primarily to higher interest rates. Interest income was \$128 million \$262 million for the quarter, period, an increase of \$86 million \$154 million versus the prior year period due primarily to higher interest rates. Other non-operating income was \$132 million \$309 million, which is a decrease an increase of \$7 million \$15 million versus the prior year period.

### Income Taxes

The effective income tax rate for the three six months ended September 30, 2023 December 31, 2023, was 21.5% 21.8%, compared to 20.7% 19.4% for the three six months ended September 30, 2022 December 31, 2022. The increase in the effective tax rate was primarily driven by 90 basis points due to the net impact of the prior year recognition of operating loss carryforwards and 150 basis points due to unfavorable impacts from the geographic mix of current period earnings. This increase was partially offset by higher excess tax benefits of share-based compensation, impacts.

### Net Earnings

Operating income increased \$828 million \$476 million, or 17% 5%, to \$5.8 billion \$10.2 billion for the quarter, period, due to the increase in net sales and the increase in operating gross margin, the components of which are described above. These benefits were partially offset by non-cash before tax impairment charges of \$1.3 billion related to Gillette intangible asset and an increase in SG&A spending as a percentage of net sales.

Net earnings increased \$593 million \$127 million, or 15% 2%, to \$4.6 billion \$8.0 billion, as the increase in operating income was partially offset by an increase in the effective tax rate. Foreign exchange had a negative impact of approximately \$170 million \$249 million on net earnings for the quarter, period, including both transactional and translational impacts from converting earnings from foreign subsidiaries to U.S. dollars. Net earnings attributable to Procter & Gamble increased \$582 million \$116 million, or 15% 1%, to \$4.5 billion \$8.0 billion for the quarter. Diluted EPS increased 17% 2% to \$1.83 \$3.23 versus the prior year period due to the increase in net earnings and a reduction in the weighted average number of shares outstanding. Core EPS, which represents diluted EPS excluding charges for incremental restructuring and the impairment of the Gillette intangible asset, increased 16% to \$3.66.

The Procter & Gamble Company 12

### SEGMENT RESULTS – Three and Six Months Ended September 30, 2023 December 31, 2023

The following discussion provides a review of results by reportable business segment. Analysis of the results for the three month period and six months ended September 30, 2023 December 31, 2023, is provided based on a comparison to the three month period and six months ended September 30, 2022 December 31, 2022. The primary financial measures used to evaluate segment performance are net sales and net earnings. The table below provides supplemental information on net sales, earnings before income taxes

and net earnings by reportable business segment for the three and six months ended **September 30, 2023** **December 31, 2023**, versus the comparable prior year period (dollar amounts in millions):

		Three Months Ended September 30, 2023								Three Months Ended December 31, 2023										
					%					%				%				%		
				Change	Earnings/(Loss)	Versus	Change	Versus		Change	Versus	Change	Versus	Change	Versus	Change	Versus			
				Year	Before Income	Year	Net	Year		Year	Before Income	Year	Net	Year	Year	Before Income	Year			
				Year Ago	Taxes	Ago	Earnings/(Loss)	Ago		Year Ago	Taxes	Ago	Earnings/(Loss)	Ago	Year Ago	Taxes	Ago			
		Net Sales	Year Ago	Taxes	Ago	Earnings/(Loss)	Ago	Net Sales		Year Ago	Taxes	Ago	Earnings/(Loss)	Ago	Net Sales	Year Ago	Taxes	Ago		
Beauty	Beauty	\$	4,097	3 %	\$	1,249	(2) %	\$	971	(4) %	Beauty	\$	3,849	1 %	\$	1,112	(3) %	\$	868	(5) %
Grooming	Grooming		1,724	6 %		533	6 %		421	4 %	Grooming		1,734	6 %		538	8 %		440	9 %
Health	Health										Health									
Care	Care		3,074	11 %		889	11 %		689	12 %	Care		3,172	4 %		932	5 %		719	5 %
Fabric & Home	Fabric & Home										Fabric & Home									
Care	Care		7,646	8 %		2,031	32 %		1,569	34 %	Care		7,415	5 %		2,018	31 %		1,577	35 %
Baby, Feminine & Family	Baby, Feminine & Family										Baby, Feminine & Family									
Care	Care		5,186	5 %		1,408	33 %		1,075	34 %	Care		5,146	2 %		1,437	29 %		1,102	30 %
Corporate	Corporate		144	N/A		(308)	N/A		(168)	N/A	Corporate		126	N/A		(1,541)	N/A		(1,214)	N/A
Total Company	Total Company	\$	21,871	6 %	\$	5,802	16 %	\$	4,556	15 %	Total Company	\$	21,441	3 %	\$	4,496	(7) %	\$	3,493	(12) %
Six Months Ended December 31, 2023																				
						%				%				%						
				Change	Earnings/(Loss)	Versus	Change	Versus	Change	Versus	Change	Versus	Change	Versus						
				Year	Before Income	Year	Year	Before Income	Year	Net	Year	Year	Before Income	Year						
				Year Ago	Taxes	Ago	Year Ago	Taxes	Ago	Earnings/(Loss)	Ago	Year Ago	Taxes	Ago						
				Net Sales	Year Ago	Taxes	Ago	Net Sales	Year Ago	Taxes	Ago	Net Sales	Year Ago	Taxes	Ago					
Beauty	Beauty	\$	7,946	2 %	\$	2,361	(2) %	\$	1,839	(4) %	Beauty	\$	7,946	2 %	\$	2,361	(2) %	\$	1,839	(4) %
Grooming	Grooming		3,458	6 %		1,071	7 %		862	7 %	Grooming		3,458	6 %		1,071	7 %		862	7 %
Health	Health										Health									
Care	Care		6,245	8 %		1,821	8 %		1,408	8 %	Care		6,245	8 %		1,821	8 %		1,408	8 %
Fabric & Home	Fabric & Home										Fabric & Home									
Care	Care		15,061	7 %		4,049	31 %		3,146	34 %	Care		15,061	7 %		4,049	31 %		3,146	34 %
Baby, Feminine & Family	Baby, Feminine & Family										Baby, Feminine & Family									
Care	Care		10,332	3 %		2,845	31 %		2,177	32 %	Care		10,332	3 %		2,845	31 %		2,177	32 %
Corporate	Corporate		270	N/A		(1,849)	N/A		(1,383)	N/A	Corporate		270	N/A		(1,849)	N/A		(1,383)	N/A
Total Company	Total Company	\$	43,312	5 %	\$	10,299	5 %	\$	8,049	2 %	Total Company	\$	43,312	5 %	\$	10,299	5 %	\$	8,049	2 %

22 The Procter & Gamble Company

## Beauty

Three months ended **September 30, 2023** **December 31, 2023**, compared with three months ended **September 30, 2022** **December 31, 2022**

Beauty net sales increased **3%** **1%** to **\$4.1 billion** **\$3.8 billion** as the positive impacts of higher pricing of **7%** **4%** and a benefit from acquisitions of 1% were partially offset by the negative impacts of unfavorable foreign exchange of 1% and unfavorable mix of 3% (due primarily to the decline of the super-premium SK-II brand, which has higher than segment-average selling prices). Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales also increased 1%. Global market share of the Beauty segment increased 0.2 points.

- Hair Care net sales increased double digits. Positive impacts of higher pricing (driven by Latin America, Europe and North America), a benefit from acquisitions, favorable product mix (due to the growth of premium products) and an increase in unit volume were partially offset by negative impacts of unfavorable foreign exchange. The volume

increase was driven by growth in North America (due to innovation), Asia Pacific (due to innovation) and Latin America (due to market growth), partially offset by a decline in Greater China (due to market contraction and distribution footprint changes). Organic sales increased high single digits driven by more than 30% growth in Latin America, mid-teens increases in Europe and North America, partially offset by a double-digit decline in Greater China. Global market share of the Hair Care category decreased 0.5 points.

- Skin and Personal Care net sales decreased high single digits. Negative impacts of unfavorable mix (due to the decline of the super-premium SK-II brand, which has higher than category-average selling prices) and a unit volume decrease were partially offset by higher pricing (driven by Greater China). The volume decrease was driven by a decline in Greater China (due to the decline of the super-premium SK-II brand and market contraction of skin care and personal care), partially offset by growth in North America and Europe (both due to innovation in Personal Care). Organic sales decreased mid-single digits due to more than 20% declines in Greater China and Asia Pacific, partially offset by a double-digit increase in North America. Global market share of the Skin and Personal Care category increased 0.4 points.

Net earnings decreased 5% to \$868 million as the increase in net sales was more than offset by a 130 basis-point decline in net earnings margin. Net earnings margin decreased as an increase in gross margin was more than fully offset by an increase in SG&A as a percentage of net sales and a higher effective tax rate. The gross margin improvement was driven by increased pricing and productivity savings, partially offset by unfavorable foreign exchange impacts and negative product mix (due to the decline of the super-premium SK-II brand). SG&A as a percentage of net sales increased due primarily to an increase in marketing and overhead spending, partially offset by the positive scale effects of the net sales increase. The higher effective tax rate was driven by unfavorable geographic mix.

Six months ended December 31, 2023, compared with six months ended December 31, 2022

Beauty net sales increased 2% to \$7.9 billion, as the positive impacts of higher pricing of 5% and a benefit from acquisitions of 1% were partially offset by the negative impacts of unfavorable foreign exchange of 2% and unfavorable mix of 2% (due primarily to the decline of the super-premium SK-II brand, which has higher than segment-average selling prices). Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 5% 3%. Global market share of the Beauty segment increased 0.3 0.2 points.

- Hair Care net sales increased high single digits. Positive impacts of higher pricing (driven by North America, Latin America, Europe and Europe North America), a benefit from acquisitions and favorable product mix (due to the growth of premium products) were partially offset by negative impacts of unfavorable foreign exchange exchange. Unit volume was unchanged as growth in Latin America and a decline in unit volume. The volume decrease was driven North America were offset by a decline in Greater China (due to market contraction and distribution footprint changes), partially offset by growth in Latin America and Europe (both due to market growth). Organic sales increased high single digits driven by a due to more than 30% growth in Latin America, a mid-teens increase in Europe and a double-digit low-teens increase in North America, partially offset by a high single-digit decline in Greater China. Global market share of the Hair Care category decreased 0.2 0.4 points.
- Skin and Personal Care net sales were unchanged. Positive impacts of higher pricing (across all regions) and a unit volume increase were offset by the negative decreased low single digits. Negative impacts of unfavorable mix (due to the decline of the super-premium SK-II brand, which has higher than category-average selling prices) and unfavorable foreign exchange. The exchange were partially offset by the positive impacts of higher pricing (across all regions). Unit volume increase was driven by unchanged as growth in North America and Europe (both due to innovation in Personal Care), partially was offset by a decline in Asia Pacific and Greater China both due (due to the decline of the super-premium SK-II brand, brand and market contraction of skin care and personal care). Organic sales increased decreased low single digits, as a double-digit increase in North America was partially offset by due to a more than 20% decline in Asia Pacific and a mid-single-digit low-teens decline in Greater China, China, partially offset by a double-digit increase in North America. Global market share of the Skin and Personal Care category increased 0.6 0.5 points.

Net earnings decreased 4% to \$971 million \$1.8 billion, as the increase in net sales was more than offset by a 180 160 basis-point decline in net earnings margin. Net earnings margin decreased as an increase in gross margin was more than fully offset by an increase in SG&A as a percentage of net sales and a higher effective tax rate. The gross margin improvement was driven by increased pricing and productivity savings, partially offset by negative product mix (due to the decline of the super-premium SK-II brand) and unfavorable foreign exchange impacts. SG&A as a percentage of net sales increased due primarily to an increase in marketing and overhead spending and higher foreign exchange transactional charges, partially offset by the positive scale

The Procter & Gamble Company 23

effects of the net sales increase. The higher effective tax rate was driven by unfavorable geographic mix.

#### Grooming

Three months ended September 30, 2023 December 31, 2023, compared with three months ended September 30, 2022 December 31, 2022

Grooming net sales increased 6% to \$1.7 billion as the benefits of higher pricing of 9% 7% (driven primarily by all regions) Europe and Latin America), a 1% increase in unit volume and favorable product mix of 1% (due to the growth of appliances) premium shavers) were partially offset by unfavorable foreign exchange of 3% and a decrease in unit volume of 2%. The volume decline growth was driven primarily by Europe Latin America (due to increased pricing), partially offset by growth in IMEA market growth) and Latin America (both due Asia Pacific (due to innovation). Excluding the impact of acquisitions and divestitures and foreign exchange, Grooming organic sales increased 9% driven by growth across all regions led by a more than 30% growth in Latin America, low-teens growth in Asia Pacific and a double-digit growth in Europe. Europe, partially offset by a low single-digit decline in North America. Global market share of the Grooming segment increased 0.3 0.8 points.

13 The Procter & Gamble Company

Net earnings increased 4% 9% to \$421 million as the \$440 million due to net sales growth was partially offset by a 40 and an 80 basis-point decrease increase in net earnings margin. Net earnings margin decreased as increased due to an increase in gross margin, was more than fully partially offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by higher pricing and productivity savings, partially offset by negative gross margin product mix (due to the growth of appliances, which have

lower than segment-average gross margins) and unfavorable foreign exchange. SG&A as a percentage of net sales increased due primarily to an increase in marketing spending, partially offset by the positive scale effects of the net sales increase.

Six months ended December 31, 2023, compared with six months ended December 31, 2022

Grooming net sales increased 6% to \$3.5 billion as the benefits of higher pricing of 8% (driven primarily by Europe and Latin America) and favorable product mix of 1% (due to growth of premium shavers) were partially offset by unfavorable foreign exchange of 3% and a 1% decrease in unit volume. The volume decrease was due to declines in Europe (due to increased pricing) and Greater China (due to market decline), partially offset by growth in Latin America and IMEA (both due to innovation). Excluding the impact of acquisitions and divestitures and foreign exchange, Grooming organic sales increased 9% due to more than 30% growth in Latin America and double-digit growth in Europe. Global market share of the Grooming segment increased 0.5 points.

Net earnings increased 7% to \$862 million, due to net sales growth and a 20 basis-point increase in net earnings margin. Net earnings margin increased due to an increase in gross margin, partially offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by higher pricing and productivity savings, partially offset by unfavorable foreign exchange. SG&A as a percentage of net sales increased due to an increase in marketing spending and higher foreign exchange transactional charges, partially offset by the positive scale effects of the net sales increase.

#### Health Care

Three months ended September 30, 2023 December 31, 2023, compared with three months ended September 30, 2022 December 31, 2022

Health Care net sales increased 11% 4% to \$3.1 billion \$3.2 billion driven by higher pricing of 6% 5%, favorable product mix of 2%, an increase in unit volume of 2% 1% and favorable foreign exchange of 1%. 2%, partially offset by a 3% decrease in unit volume. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 10% 2%. Global market share of the Health Care segment increased 1 point 0.7 points.

- Oral Care net sales increased high single mid-single digits driven by the positive impacts of higher pricing (driven by Europe, North America and Latin America), favorable product mix (due to growth in power brushes, of premium paste, which have higher than category-average selling prices) and favorable foreign exchange. Unit volume was unchanged, as exchange, partially offset by a decline in Greater China (due unit volume. The decrease in unit volume was driven primarily by declines in IMEA and Latin America (both due to market contraction) was offset by growth in North America (due to market growth) share losses). Organic sales increased high single mid-single digits driven by a mid-teens double-digit increase in Europe and a mid-single-digit increase in North America. Global market share of the Oral Care category increased 0.2 0.3 points.
- Personal Health Care net sales increased low teens single digits as the positive impacts of higher pricing (driven by North America, Europe and Latin America) and favorable foreign exchange were partially offset by a unit volume decrease and unfavorable mix (due to the decline of respiratory products, which have higher than category-average selling prices). The volume decrease was driven primarily by declines in Europe and Latin America (both due to market decline of respiratory products). Organic sales decreased low single digits driven by a double-digit decline in Europe, a mid-single-digit decline in Latin America, partially offset by low single-digit growth in North America. Global market share of the Personal Health Care category increased 0.6 points.

Net earnings increased 5% to \$719 million due to the net sales growth and a 20 basis-point increase in net earnings margin. Net earnings margin increased due to an increase in gross margin, partially offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by higher pricing and productivity savings, partially offset by unfavorable gross margin product mix (due to a decline in respiratory products, which have higher than segment-average gross margins). SG&A as a percentage of net sales increased due to increased marketing and overhead spending, partially offset by the positive scale impacts of the net sales increase.

Six months ended December 31, 2023, compared with six months ended December 31, 2022

Health Care net sales increased 8% to \$6.2 billion driven by higher pricing of 5%, favorable product mix of 2% and favorable foreign exchange of 2%, partially offset by a 1% decrease in unit volume. Excluding the impact of acquisitions and divestitures

---

24 The Procter & Gamble Company

and foreign exchange, organic sales increased 6%. Global market share of the Health Care segment increased 0.8 points.

- Oral Care net sales increased high single digits due to the positive impacts of higher pricing (driven by Europe, North America and Latin America), favorable product mix (due to growth of premium paste and power brushes, which have higher than category-average selling prices) and favorable foreign exchange, partially offset by a decrease in unit volume. The unit volume decrease was due to a decline in Latin America (due to share losses), IMEA and Greater China (due to market contraction) partially offset by growth in Europe (due to market growth). Organic sales also increased high single digits due to a double-digit increase in Europe and a mid-single-digit increase in North America. Global market share of the Oral Care category increased 0.3 points.
- Personal Health Care net sales increased high single digits due to the positive impacts of higher pricing (driven by North America, Europe and Latin America), a unit volume increase and favorable foreign exchange. The exchange, partially offset by unfavorable mix (due to the decline of respiratory products, that have higher than category-average selling prices). Unit volume increase was driven by unchanged as growth in North America (due to innovation and increased demand for respiratory products) and Europe (due to increased demand for respiratory products), partially innovation) was offset by a decline declines in Asia Pacific (due and Latin America (both due to market contraction). Organic sales increased double mid-single digits driven by a more than 20% growth in Europe and a low teens due to high single-digit growth in North America. America and mid-single-digit growth in Europe. Global market share of the Personal Health Care category increased 1.1 0.8 points.

Net earnings increased 12% 8% to \$689 million \$1.4 billion due to the increase in net sales. Net earnings margin was unchanged as an increase in gross margin was offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by higher pricing and productivity savings, partially offset by unfavorable gross margin product mix (due to a decline in respiratory and whitening products, both of which have higher than segment-average gross margins). SG&A as a percentage of net sales increased due to increased marketing and overhead spending, partially offset by the positive scale impacts of the net sales increase.

#### Fabric & Home Care

Three months ended September 30, 2023 December 31, 2023, compared with three months ended September 30, 2022 December 31, 2022

Fabric & Home Care net sales increased 8% 5% to \$7.6 billion \$7.4 billion driven by higher pricing of 8% 4% and favorable product mix of 1%, partially offset by a decrease in unit volume of 1% and unfavorable foreign exchange of 1%. remained unchanged. Excluding the impact of foreign exchange and acquisitions and divestitures, organic sales increased 9% 6%. Global market share of the Fabric & Home Care segment increased 0.2 0.3 points.

- Fabric Care net sales increased mid-single digits. The digits due to the positive impacts of higher pricing (driven by Europe, IMEA Asia Pacific and Latin America) and favorable premium product mix. Volume was unchanged as growth in North America was fully offset by declines in Greater China (due to market contraction and portfolio rationalization), Asia Pacific (due to share losses) and IMEA (due to increased pricing). Organic sales increased mid-single digits driven by a high single-digit increase in Europe and a mid-single-digit increase in North America. Global market share of the Fabric Care category decreased 0.2 points.
- Home Care net sales increased high single digits. Positive impacts of higher pricing (driven primarily by Europe and Latin America), a unit volume increase and favorable premium product mix were partially offset by a decrease in unit volume and unfavorable foreign exchange. The increase in unit volume decrease was due primarily to growth in North America (due to innovation), partially offset by decline in Asia Pacific (due to increased pricing). Organic sales increased high single digits driven by low-teens growth in Europe and high single-digit growth in North America. Global market share of the Home Care category increased 1.2 points.

Net earnings increased 35% to \$1.6 billion due to the increase in net sales and a 460 basis-point improvement in net earnings margin. Net earnings margin increased due to an increase in gross margin partially offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by increased productivity savings, higher pricing and lower commodity costs. SG&A as a percentage of net sales increased due to an increase in marketing spending, partially offset by the positive scale effects of the net sales increase.

Six months ended December 31, 2023, compared with six months ended December 31, 2022

Fabric & Home Care net sales increased 7% to \$15.1 billion driven by higher pricing of 6% and favorable product mix of 1%, partially offset by unfavorable foreign exchange of 1%. Unit volume was unchanged. Excluding the impact of foreign exchange and acquisitions and divestitures, organic sales increased 8%. Global market share of the Fabric & Home Care segment increased 0.3 points.

- Fabric Care net sales increased mid-single digits driven by the positive impacts of higher pricing (driven by Europe, Latin America, IMEA and Asia Pacific) and favorable premium product mix. Unit volume was unchanged as growth in North America (due to market growth) was offset by declines in Greater China (due to market contraction and portfolio rationalization) and Asia Pacific (due to increased pricing), partially offset by growth in North America (due to market growth) and Europe. Organic sales also increased high single mid-single digits driven by a more than 20% low-teens increase in Europe a mid-teens increase in IMEA and a low single-digit mid-single-digit increase in North America. Global market share of the Fabric Care category decreased 0.3 0.2 points.
- Home Care net sales increased double digits. Positive impacts of higher pricing (driven primarily by Europe, North America and North Latin America) and, favorable premium product mix and a unit volume increase were partially offset by

The Procter & Gamble Company 25

unfavorable foreign exchange. Unit The increase in volume was unchanged as due to growth in North America (due to innovation) was, partially offset by declines in Europe and Latin America (both due to increased pricing). Organic sales increased low teens double digits driven by a 20% mid-teens growth in Europe and double-digit growth in North America. Global market share of the Home Care category increased 1.1 1.2 points.

Net earnings increased 34% to \$1.6 billion \$3.1 billion due to the increase in net sales and a 400 430 basis-point improvement in net earnings margin. Net earnings margin increased due to an increase in gross margin partially offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by higher pricing, lower commodity costs and increased productivity savings partially offset by unfavorable foreign exchange, and lower commodity costs. SG&A as a percentage of net sales increased due to an increase in marketing spending, partially offset by the positive scale effects of the net sales increase.

#### Baby, Feminine & Family Care

Three months ended September 30, 2023 December 31, 2023, compared with three months ended September 30, 2022 December 31, 2022

Baby, Feminine & Family Care net sales increased 5% 2% to \$5.2 billion \$5.1 billion driven by higher pricing of 8% 4% and favorable product mix of 2% 1%, partially offset by a 2% decrease in unit volume of 3% and unfavorable foreign exchange of 2% 1%. Excluding the impacts of

The Procter & Gamble Company 14

foreign exchange and acquisitions and divestitures, organic sales increased 7% 3%. Global market share of the Baby, Feminine & Family Care segment decreased 0.2 0.1 points.

- Baby Care net sales decreased low single digits. Positive impacts of higher pricing (driven by Latin America, Europe, IMEA and North America) and favorable product mix (due to growth of premium diapers, which have higher than category-average selling prices) were partially offset by a decrease in unit volume and unfavorable foreign exchange. Volumes decreased in all regions led by Europe, IMEA and North America, all due to increased pricing. Organic sales were unchanged as mid-teens growth in Latin America was offset by mid-single-digit declines in IMEA and Europe. Global market share of the Baby Care category decreased 0.1 points.
- Feminine Care net sales increased low single digits. Positive impacts of higher pricing (driven primarily by Europe, Latin America and IMEA) and favorable mix (due to growth of premium products) were partially offset by a decrease in unit volume and unfavorable foreign exchange. The volume decrease was primarily driven by declines in Europe, IMEA (both due to increased pricing) and Greater China (due to market decline). Organic sales increased mid-single digits driven by a mid-single-digit increase in Europe and a low single-digit increase in North America. Global market share of the Feminine Care category increased 0.1 points.
- Net sales in Family Care, which is predominantly a North America business, increased mid-single digits driven by an increase in unit volume and higher pricing, partially offset by unfavorable product mix (due to growth of larger pack sizes, with lower than category-average selling prices). Organic sales also increased mid-single digits. North America market share of the Family Care category decreased 0.4 points.



Net earnings increased 30% to \$1.1 billion due to the increase in net sales and a 460 basis-point increase in net earnings margin. Net earnings margin increased primarily due to an increase in gross margin, partially offset by an increase in SG&A as a percentage of net sales. Gross margin increased primarily due to lower commodity costs, increased productivity savings and increased pricing, partially offset by unfavorable foreign exchange. SG&A as a percentage of net sales increased due to an increase in marketing and overhead spending, partially offset by the positive scale impacts of the net sales increase.

Six months ended December 31, 2023, compared with six months ended December 31, 2022

Baby, Feminine & Family Care net sales increased 3% to \$10.3 billion driven by higher pricing of 6% and favorable product mix of 1%, partially offset by a 2% decrease in unit volume and unfavorable foreign exchange of 1%. Excluding the impacts of foreign exchange and acquisitions and divestitures, organic sales increased 5%. Global market share of the Baby, Feminine & Family Care segment decreased 0.1 points.

- Baby Care net sales increased mid-single low single digits. Positive impacts of higher pricing (driven by Europe, Latin America, North America and IMEA) and favorable product mix (due to growth of premium diapers, which have higher than category-average selling prices) were partially offset by a decrease in unit volume and unfavorable foreign exchange. Volumes decreased in all regions led by Europe and North America, all due to increased pricing. Organic sales increased mid-single low single digits driven by growth in all regions led by a 30% more than 20% growth in Latin America, and a mid-teens mid-single-digit growth in IMEA, IMEA and low single-digit growth in North America. Global market share of the Baby Care category decreased 0.4 0.2 points.
- Feminine Care net sales increased mid-single digits. Positive impacts of higher pricing (driven primarily by Europe, IMEA and IMEA Latin America) and favorable mix (due to growth of premium products) were partially offset by unfavorable foreign exchange and a decrease in unit volume, volume and unfavorable foreign exchange. The volume decrease was driven primarily driven by declines in Europe Latin America and IMEA (all (both due to increased pricing) and Greater China (due to market decline), partially offset by growth in North America (due to increased demand for premium products and distribution gains). Organic sales increased high single mid-single digits driven by a double-digit increase in IMEA, high single-digit increase in Europe and a high single-digit mid-single-digit increase in North America. Global market share of the Feminine Care category increased 0.3 0.4 points.

---

## 26 The Procter & Gamble Company

- Net sales in Family Care, which is predominantly a North America business, increased mid-single digits driven by higher pricing and unit volume increase, partially offset by unfavorable product mix (due to growth of larger pack sizes, with lower than category-average selling prices). Unit volume was unchanged. Organic sales also increased mid-single digits. North America market share of the Family Care category decreased 0.5 0.3 points.

Net earnings increased 34% 32% to \$1.1 billion \$2.2 billion due to the increase in net sales and a 440 460 basis-point increase in net earnings margin. Net earnings margin increased primarily due to an increase in gross margin, partially offset by an increase in SG&A as a percentage of net sales. Gross margin increased primarily due to increased pricing, lower commodity costs, increased pricing and increased productivity savings, partially offset by unfavorable foreign exchange. SG&A as a percentage of net sales increased due to an increase in marketing and overhead spending and higher foreign exchange transactional charges, partially offset by the positive scale impacts of the net sales increase.

### Corporate

Corporate includes certain operating and non-operating activities not allocated to specific business segments. These include but are not limited to incidental businesses managed at the corporate level, gains and losses related to certain divested brands or businesses, impacts from various financing and investing activities, impacts related to employee benefits, asset impairments and restructuring activities including manufacturing and workforce optimization. Corporate also includes reconciling items to adjust the accounting policies used within the reportable segments to U.S. GAAP. The most notable ongoing reconciling item is income taxes, which adjusts the blended statutory rates that are reflected in the reportable segments to the overall Company effective tax rate.

For the three months ended September 30, 2023 December 31, 2023, Corporate net sales decreased \$109 million \$49 million to \$144 million \$126 million due to a decrease in net sales of incidental businesses managed at the corporate level. Corporate net earnings decreased \$122 million to a loss of \$168 million \$1.2 billion for the quarter primarily due to the impairment of the Gillette intangible asset, increased interest expense and higher restructuring charges charges.

For the six months ended December 31, 2023, Corporate net sales decreased \$158 million to \$270 million due to a decrease in net sales of incidental businesses managed at the corporate level. Corporate net earnings decreased to a loss of \$1.4 billion due to the impairment charge of the Gillette intangible asset, increased interest expense and higher interest expense net of interest income, restructuring charges.

## LIQUIDITY & CAPITAL RESOURCES

### Operating Activities

Operating cash flow was \$4.9 billion \$10.0 billion fiscal year to date, an increase of \$834 million \$2.4 billion versus the prior year period. Net earnings, adjusted for non-cash items (depreciation and amortization, intangible asset impairment, and share-based compensation expense, deferred income taxes and gain on sale of assets) expense, generated \$5.5 billion \$10.9 billion of operating cash flow. Working capital and other impacts used \$578 million \$927 million of cash in the period primarily driven by increases an increase in accounts receivable from sales growth, a reduction in salary related liabilities due to the excess of payment over accruals, and a reduction in postretirement benefit accruals resulting from the payment of prior fiscal year-end incentive compensation accruals, net periodic benefit credit and payments. This is partially offset by the impact of our supplier finance program (see Note 10, Supplier Finance Programs) and current year tax accruals in excess of payments. Days sales outstanding increased by two days, and Days inventory on hand increased by two three days.

### Investing Activities

Investing activities used \$1.2 billion \$2.2 billion of cash fiscal year to date primarily driven by capital expenditures and the settlement of net investment hedges.

### Financing Activities

Financing activities consumed \$2.0 billion used \$8.1 billion of net cash fiscal year to date, mainly due to dividends to shareholders, and treasury stock purchases, partially offset by and a net debt increase and decrease, partially offset by the impact of stock options and other.

As of September 30, 2023 December 31, 2023, our current liabilities exceeded current assets by \$12.2 billion \$12.8 billion. We anticipate being able to support our short-term liquidity and operating needs largely through cash generated from operations. We have strong short- and long-term debt ratings that have enabled and should continue to enable us

to refinance our debt as it becomes due at favorable rates in commercial paper and bond markets. In addition, we have agreements with a diverse group of financial institutions that, if needed, should provide sufficient credit funding to meet short-term financing requirements.

## MEASURES NOT DEFINED BY U.S. GAAP

In accordance with the SEC's Regulation S-K Item 10(e), the following provides definitions of the non-GAAP measures and the reconciliation to the most closely related GAAP measure. We believe that these measures provide useful perspective on underlying business trends (i.e., trends excluding non-recurring or unusual items) and results and provide a supplemental measure of period-to-period results. The non-GAAP measures described below are used by management in making operating decisions, allocating financial resources and for business strategy purposes. These measures may be useful to investors, as they provide supplemental information about business performance and provide investors a view of our business results through the eyes of management. These measures are also used to evaluate senior management and are a factor in determining their at-risk compensation. These non-GAAP measures are not intended to be considered by the user in place of the related GAAP measures but rather as supplemental information to our business results. These non-GAAP measures may not be the same as similar measures used by other companies due to possible differences in method and in the items or events being adjusted.

**Organic sales growth:** Organic sales growth is a non-GAAP measure of sales growth excluding the impacts of acquisitions and divestitures and foreign exchange from year-over-year comparisons. We believe this measure provides investors with a supplemental understanding of underlying sales trends by providing sales growth on a consistent basis. This measure is used in assessing the achievement of management goals for at-risk compensation.

The following table provides a numerical reconciliation of organic sales growth to reported net sales growth:

Three Months Ended September 30, 2023	Acquisition & Divestiture			
	Net Sales Growth	Foreign Exchange Impact	Impact/Other <sup>(1)</sup>	Organic Sales Growth
Beauty	3 %	3 %	(1)%	5 %
Grooming	6 %	3 %	— %	9 %
Health Care	11 %	(1)%	— %	10 %
Fabric & Home Care	8 %	1 %	— %	9 %
Baby, Feminine & Family Care	5 %	2 %	— %	7 %
<b>Total Company</b>	<b>6 %</b>	<b>1 %</b>	<b>— %</b>	<b>7 %</b>

<sup>(1)</sup> Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to organic sales.

Three Months Ended December 31, 2023	Acquisition & Divestiture			
	Net Sales Growth	Foreign Exchange Impact	Impact/Other <sup>(1)</sup>	Organic Sales Growth
Beauty	1 %	1 %	(1)%	1 %
Grooming	6 %	3 %	— %	9 %
Health Care	4 %	(2)%	— %	2 %
Fabric & Home Care	5 %	— %	1 %	6 %
Baby, Feminine & Family Care	2 %	1 %	— %	3 %
<b>Total Company</b>	<b>3 %</b>	<b>1 %</b>	<b>— %</b>	<b>4 %</b>

<sup>(1)</sup> Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to organic sales.

Six Months Ended December 31, 2023	Acquisition & Divestiture			
	Net Sales Growth	Foreign Exchange Impact	Impact/Other <sup>(1)</sup>	Organic Sales Growth
Beauty	2 %	2 %	(1)%	3 %
Grooming	6 %	3 %	— %	9 %
Health Care	8 %	(2)%	— %	6 %
Fabric & Home Care	7 %	1 %	— %	8 %
Baby, Feminine & Family Care	3 %	1 %	1 %	5 %
<b>Total Company</b>	<b>5 %</b>	<b>1 %</b>	<b>(1)%</b>	<b>5 %</b>

<sup>(1)</sup> Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to organic sales.



**Adjusted free cash flow:** Adjusted free cash flow is defined as operating cash flow less capital expenditures and excluding payments for the transitional tax resulting from the U.S. Tax Act. Adjusted free cash flow represents the cash that the Company is able to generate after taking into account planned maintenance and asset expansion. We view adjusted free cash flow as an important measure because it is one factor used in determining the amount of cash available for dividends, share repurchases, acquisitions and other discretionary investments.

The following table provides a numerical reconciliation of adjusted free cash flow (\$ millions):

Three Months Ended September 30, 2023				
Operating Cash Flow	Capital Spending	U.S. Tax Act Payments	Adjusted Free Cash Flow	
\$ 4,904	\$ (925)	\$ 422	\$ 4,401	

Six Months Ended December 31, 2023				
Operating Cash Flow	Capital Spending	U.S. Tax Act Payments	Adjusted Free Cash Flow	
\$ 10,004	\$ (1,742)	\$ 422	\$ 8,684	

**Adjusted free cash flow productivity:** Adjusted free cash flow productivity is defined as the ratio of adjusted free cash flow to net earnings, earnings excluding the Gillette intangible asset impairment charge. We view adjusted free cash flow productivity as a useful measure to help investors understand P&G's ability to generate cash. Adjusted free cash flow productivity is used by management in making operating decisions, in allocating financial resources and for budget planning purposes. This measure is also used in assessing the achievement of management goals for at-risk compensation.

The following table provides a numerical reconciliation of adjusted free cash flow productivity (\$ millions):

Three Months Ended September 30, 2023									
Six Months Ended December 31, 2023					Six Months Ended December 31, 2023				
Adjusted Free Cash Flow	Adjusted Free Cash Flow	Net Earnings	Adjusted Free Cash Flow Productivity	Adjusted Free Cash Flow	Net Earnings	Adjustments to Net Earnings (1)	Net Earnings as Adjusted	Adjusted Free Cash Flow Productivity	
\$ 4,401	\$ 4,556	97	%	8,684	\$ 8,049	\$ 1,026	\$ 9,075	96	%
(1) Adjustments to Net Earnings relate to the Gillette intangible asset impairment charge announced in December 2023.									
(1) Adjustments to Net Earnings relate to the Gillette intangible asset impairment charge announced in December 2023.									

**Core EPS:** Core EPS is a measure of the Company's diluted EPS excluding items that are not judged by management to be part of the Company's sustainable results or trends. Management views this non-GAAP measure as a useful supplemental measure of Company performance over time. This measure is also used in assessing the achievement of management goals for at-risk compensation. For The Core earnings measures included in the following reconciliation tables refer to the equivalent GAAP measures adjusted as applicable for the following items:

28 The Procter & Gamble Company

- Incremental restructuring:** The Company has historically had an ongoing level of restructuring activities of approximately \$250 - \$500 million before tax. On December 5, 2023, the Company announced a limited market portfolio restructuring of its business operations, primarily in certain Enterprise Markets, including Argentina and Nigeria. The adjustment to Core earnings includes the restructuring charges that exceed the normal, recurring level of restructuring charges.
- Intangible asset impairment:** As discussed in Note 4 to the Consolidated Financial Statements, the Company recognized in the three months ended September 30, 2023 December 31, 2023, a non-cash, after-tax impairment charge of \$1.0 billion (\$1.3 billion before tax) to adjust the carrying value of the Gillette intangible asset acquired as part of the Company's 2005 acquisition of The Gillette Company.

We do not view the above items to be part of our sustainable results, and September 30, 2022, there were no adjustments to or reconciling their exclusion from core earnings measures provides a more comparable measure of year-on-year results. These items for diluted EPS are also excluded when evaluating senior management in determining their at-risk compensation.

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
Reconciliation of Non-GAAP Measures

	Three Months Ended December 31, 2023				Three Months Ended December 31, 2022
	As Reported (GAAP)	Incremental Restructuring	Intangible Impairment	Core (Non-GAAP)	As Reported (GAAP) <sup>(1)</sup>
<b>Amounts in millions except per share amounts</b>					
Cost of products sold	\$ 10,144	\$ (12)	\$ —	\$ 10,132	\$ 10,897
Selling, general and administrative expense	5,522	(8)	—	5,515	5,091
Operating income	4,433	19	1,341	5,793	4,785
Income taxes	1,003	(20)	315	1,299	876
Net earnings attributable to P&G	3,468	39	1,026	4,533	3,933
				<b>Core EPS</b>	
Diluted net earnings per common share <sup>(2)</sup>	\$ 1.40	\$ 0.02	\$ 0.42	\$ 1.84	\$ 1.59

<sup>(1)</sup> For the three months ended December 31, 2022, there were no adjustments to or reconciling items for Core EPS.

<sup>(2)</sup> Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.

#### CHANGE VERSUS YEAR AGO

Net earnings attributable to P&G	(12)%
Core net earnings attributable to P&G	15 %
Diluted net earnings per common share	(12)%
Core EPS	16 %

The Procter & Gamble Company 16 29

#### THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES Reconciliation of Non-GAAP Measures

	Six Months Ended December 31, 2023				Six Months Ended December 31, 2022
	As Reported (GAAP)	Incremental Restructuring	Intangible Impairment	Core (Non-GAAP)	As Reported (GAAP) <sup>(1)</sup>
<b>Amounts in millions except per share amounts</b>					
Cost of products sold	\$ 20,645	\$ (12)	\$ —	\$ 20,633	\$ 21,743
Selling, general and administrative expense	11,127	(8)	—	11,119	9,918
Operating income	10,200	19	1,341	11,560	9,724
Income taxes	2,250	(20)	315	2,545	1,910
Net earnings attributable to P&G	7,988	39	1,026	9,054	7,872
				<b>Core EPS</b>	
Diluted net earnings per common share <sup>(2)</sup>	\$ 3.23	\$ 0.02	\$ 0.42	\$ 3.66	\$ 3.16

<sup>(1)</sup> For the six months ended December 31, 2022, there were no adjustments to or reconciling items for Core EPS.

<sup>(2)</sup> Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.

#### CHANGE VERSUS YEAR AGO

Net earnings attributable to P&G	1 %
Core net earnings attributable to P&G	15 %
Diluted net earnings per common share	2 %
Core EPS	16 %

#### Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in the Company's exposure to market risk since June 30, 2023. Additional information can be found in Note 9, Risk Management Activities and Fair Value Measurements, of the Company's Form 10-K for the fiscal year ended June 30, 2023.

#### Item 4. Controls and Procedures

##### Evaluation of Disclosure Controls and Procedures

The Company's Chairman of the Board, President and Chief Executive Officer, Jon R. Moeller, and the Company's Chief Financial Officer, Andre Schulten, performed an evaluation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (Exchange Act)) as of the end of the period covered by this report.

Messrs. Moeller and Schulten have concluded that the Company's disclosure controls and procedures were effective to ensure that information required to be disclosed in reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (2) accumulated and communicated to our management, including Messrs. Moeller and Schulten, to allow their timely decisions regarding required disclosure.

#### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the Company's fiscal quarter ended **September 30, 2023** **December 31, 2023**, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

## PART II. OTHER INFORMATION

### Item 1. Legal Proceedings

The Company is subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust and trade regulation, product liability, advertising, contracts, environmental issues, patent and trademark matters, labor and employment matters and tax. In addition, SEC regulations require that we disclose certain environmental proceedings arising under Federal, State or local law when a governmental authority is a party and such proceeding involves potential monetary sanctions that the Company reasonably believes will exceed a certain threshold (\$1 million or more).

On November 22, 2023, Procter & Gamble UK ("P&G UK"), a United Kingdom based wholly owned subsidiary of the Company, received notification from the U.K. Environment Agency of its intent to assess an unspecified civil penalty for P&G UK's prior inadvertent failure to secure a required permit for its London-based manufacturing site under the European Union's and United Kingdom's Emission Trading Systems. Among other requirements, these Emissions Trading Systems require

30 The Procter & Gamble Company

registration of the site and accounting of and payment for certain past greenhouse gas emissions. The site has been properly registered since March 2021, and P&G UK proactively notified the U.K. Environment Agency after learning of the prior issue.

There are no other relevant matters to disclose under this Item for this period.

### Item 1A. Risk Factors

For information on risk factors, please refer to "Risk Factors" in Part I, Item 1A of the Company's Form 10-K for the fiscal year ended June 30, 2023.

### Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities

#### ISSUER PURCHASES OF EQUITY SECURITIES

Period	Total Number of Shares Purchased <sup>(1)</sup>	Average Price Paid per Share <sup>(2)</sup>	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs <sup>(3)</sup>	Approximate Dollar Value of Shares That May Yet Be Purchased Under Our Share Repurchase Program
7/01/2023 - 7/31/2023	7,834,268	\$151.24	6,613,447	<sup>(3)</sup>
8/01/2023 - 8/31/2023	3,227,792	\$154.89	3,227,792	<sup>(3)</sup>
9/01/2023 - 9/30/2023	—	—	—	<sup>(3)</sup>
<b>Total</b>	<b>11,062,060</b>	<b>\$152.31</b>	<b>9,841,239</b>	

Period	Total Number of Shares Purchased <sup>(1)</sup>	Average Price Paid per Share <sup>(2)</sup>	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs <sup>(3)</sup>	Approximate Dollar Value of Shares That May Yet Be Purchased Under Our Share Repurchase Program
10/01/2023 - 10/31/2023	—	—	—	<sup>(3)</sup>
11/01/2023 - 11/30/2023	3,311,725	\$150.98	3,311,725	<sup>(3)</sup>
12/01/2023 - 12/31/2023	3,411,865	146.55	3,411,865	<sup>(3)</sup>
<b>Total</b>	<b>6,723,590</b>	<b>\$148.73</b>	<b>6,723,590</b>	

<sup>(1)</sup> All transactions are reported on a trade date basis and were made in the open market with large financial institutions. This table excludes shares withheld from employees to satisfy tax withholding requirements on option exercises and other equity-based transactions. The Company administers cashless exercises through an independent third party and does not repurchase stock in connection with cashless exercises.

<sup>(2)</sup> Average price paid per share for open market transactions excludes commission.

<sup>(3)</sup> In accordance with the repurchase program announced on July 28, 2023, the Company reaffirmed in its earnings release on **October 18, 2023** **January 23, 2024**, that it expects to reduce outstanding shares through direct share repurchases at a value of \$5 to \$6 billion in fiscal year 2024, notwithstanding any purchases under the Company's compensation and benefit plans. Purchases may be made in the open market and/or private transactions and purchases may be increased, decreased or discontinued at any time without prior notice. The share repurchases are authorized pursuant to a resolution issued by the Company's Board of Directors and are expected to be financed by a combination of operating cash flows and issuance of debt.

**Item 5. Other Information**

During the three months ended **September 30, 2023** **December 31, 2023**, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" as defined in Item 408 of Regulation S-K.

The Procter &amp; Gamble Company 31

**Item 6. Exhibits**

[3-1 Amended Articles of Incorporation \(as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the Board of Directors on April 8, 2016\) \(Incorporated by reference to Exhibit \(3-1\) of the Company's Form 10-K for the year ended June 30, 2016\)](#)

[3-2 Regulations \(as approved by the Board of Directors on December 13, 2022, pursuant to authority granted by shareholders at the annual meeting on October 13, 2009\) \(Incorporated by reference to Exhibit \(3-2\) of the Company's Current Report on Form 8-K filed December 13, 2022\)](#)

[10-14-1 Summary Indenture, dated as of September 3, 2009, between the Company and Deutsche Bank Trust Company Americas, as Trustee \(Incorporated by reference to Exhibit \(4-1\) of the Company's Short Term Achievement Reward Program Annual Report on Form 10-K for the year ended June 30, 2015\)\\* +](#)

[10-2 Short Term Achievement Reward Program – related correspondence and terms and conditions\\* +](#)

[10-3 The Procter & Gamble Performance Stock Program Summary\\* +](#)

[10-4 Performance Stock Program related correspondence and terms and conditions\\* +](#)

[10-5 Long-Term Incentive Program related correspondence and terms and conditions\\* +](#)

[10-6 The Procter & Gamble 2019 Stock and Incentive Compensation Plan – Additional terms and conditions\\* +](#)

[31.1 Rule 13a-14\(a\)/15d-14\(a\) Certification – Chief Executive Officer +](#)

[31.2 Rule 13a-14\(a\)/15d-14\(a\) Certification – Chief Financial Officer +](#)

[32.1 Section 1350 Certifications – Chief Executive Officer +](#)

[32.2 Section 1350 Certifications – Chief Financial Officer +](#)

101.SCH <sup>(1)</sup> Inline XBRL Taxonomy Extension Schema Document

101.CAL <sup>(1)</sup> Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF <sup>(1)</sup> Inline XBRL Taxonomy Definition Linkbase Document

101.LAB <sup>(1)</sup> Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE <sup>(1)</sup> Inline XBRL Taxonomy Extension Presentation Linkbase Document

104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

\* Compensatory plan or arrangement

+ Filed herewith

<sup>(1)</sup> Pursuant to Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 or 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

THE PROCTER & GAMBLE COMPANY

**October 18, 2023** **January 23, 2024**

Date

/s/ MATTHEW W. JANZARUK

(Matthew W. Janzaruk)

Senior Vice President - Chief Accounting Officer

(Principal Accounting Officer)

## Exhibit (10-1)

### Summary of the Company's Short Term Achievement Reward Program

#### **SHORT TERM ACHIEVEMENT REWARD PROGRAM** **(Effective July 1, 2023)**

The Short-Term Achievement Reward ("STAR") Program is The Procter & Gamble Company's (the "Company") annual bonus program designed to motivate and reward employees for achieving outstanding short-term business results for the Company and its subsidiaries. STAR awards are made pursuant to authority delegated to the Compensation & Leadership Development Committee (the "C&LD Committee") by the Board of Directors for awarding compensation to the Company's principal officers and for making awards under the Procter & Gamble 2019 Stock and Incentive Compensation Plan (the "2019 Plan") or any successor stock plan approved in accordance with applicable listing standards.

#### **I. ELIGIBILITY**

Employees at Band 1 or above and who worked at least 28 days (four calendar weeks) during the applicable fiscal year are eligible to participate. Eligible employees who do not work a full schedule (e.g., leaves of absence, disability, and less-than-full time schedules) in the fiscal year in which the award is payable may have awards pro-rated.

#### **II. CALCULATION**

The individual STAR Award is calculated as follows:

**$(\text{STAR Target}) \times [ (\text{Business Unit Performance Factor} \times 70\% \text{ weighting}) + (\text{Total Company Performance Factor} \times 30\% \text{ weighting}) ]$**

- The **STAR Target** for each participant is calculated as:

(Base Salary) x (STAR Target percent) where *Base Salary* at the end of the applicable fiscal year is used to calculate the STAR award; except in cases where an employee has a reduction in salary during the fiscal year, in which case the salary would be prorated, or in cases where an employee becomes ineligible for the program during the fiscal year, in which case base salary as of the end of the STAR eligible level will be used. Base salary may also include certain allowances where the inclusion of these allowances in base pay is the predominant market practice. The Head of Total Rewards will review and approve any countries and allowances that will be included in base pay for purposes of the STAR award calculation. Generally, the *STAR Target Percent* is dependent on the individual's position and level (Band) in the organization. The STAR Target percent for participants at Band 7 or above is set by the C&LD Committee. The STAR Target percent for all other participants is set by the Chief Executive Officer, with the concurrence of the Chief Human Resources Officer, pursuant to authority delegated to them by the C&LD Committee. If an individual's position and/or level changes during a fiscal year, and that change results in a new STAR Target Percent, the STAR Target Percent is pro-rated according to the amount of time in each position/level during the fiscal year.

- The **Business Unit Performance Factor** is weighted at 70% and is based on the fiscal year success for the appropriate STAR business unit. The STAR business units are

---

defined by the Chief Human Resources Officer and may consist of business categories, segments, geographies, functions, organizations or a combination of one or more of these items. The STAR business units will be defined within ninety (90) days of the beginning of the fiscal year but may be adjusted as necessary to reflect business and/or organizational changes (e.g., reorganization, acquisition, merger, divestiture, etc.). The Business Unit Performance Factors can range from 0% to 200% with a target of 100%. In general, a committee consisting of at least two of the Chief Executive Officer, Chief Financial Officer, Chief Human Resources Officer and/or the Chief Operating Officer (the "STAR Committee"), conducts a comprehensive retrospective assessment of the fiscal year performance of each STAR business unit against previously established goals and relative to competition for one or more of the following measures: Operating Total Shareholder Return, After Tax Profit, Free Cash Flow Productivity, Value Share, Organic Sales, Internal controls, Accounts receivable, Inventory, Organization Head Self-Assessment, and Cross Organization Assessment. The STAR Committee makes a recommendation of an appropriate Business Unit Performance Factor to the C&LD Committee. There may also be other factors significantly affecting STAR business unit results positively or negatively which can be considered by the STAR Committee when making its recommendation. No member of the STAR Committee makes any recommendation or determination as to their own STAR award. As a result, there are certain instances in which a Business Unit Performance Factor recommendation to the C&LD Committee must be made exclusively by the Chief Executive Officer.

Business Unit leaders may then allocate the approved STAR Business Unit Factors among the divisions of the Business Unit to more closely align the STAR award with performance, so long as the total expenditure does not exceed that approved by the STAR Committee and no individual STAR award exceeds 200% of target.

- The **Total Company Performance Factor** is weighted at 30% and is based on the total Company's success during the fiscal year and ranges from 0% to 200%, with a target of 100%. The same Total Company Performance Factor is applied to all STAR award calculations, regardless of STAR business unit. It is determined using a matrix which compares results against pre-established goals for fiscal year organic sales growth and core earnings per share ("EPS") growth for the fiscal year. For participants who are members of the Global Leadership Council (GLC) at any time during the fiscal year, an ESG Factor will be applied to the Total Company Performance Factor. The ESG Factor will be based on an ESG scorecard approved by the C&LD Committee in the August meeting at the start of the fiscal year. Based on a retrospective assessment of final fiscal year results, a factor in the range of 80% - 120% will be assigned and multiplied by the Total Company Performance Factor to determine final awards. Application of the ESG Factor may not cause the final award to exceed the 200% of target maximum.

While the STAR Committee makes recommendations to the C&LD Committee regarding the Business Unit and Total Company performance factors to be applied to all STAR awards (except those for the STAR Committee members), only the final award amounts for principal officers are approved specifically by the C&LD Committee. The C&LD Committee has delegated the approval of STAR awards for other participants to the Chief Executive Officer. The C&LD Committee has discretion to use, increase or decrease the performance factors recommended by the STAR Committee and/or to choose not to pay STAR awards during a given year.

---

### III. TIMING AND FORM

STAR awards are determined after the close of the fiscal year and are paid on or about September 15. The award form choices and relevant considerations are explained to participants annually. Participants receive written notice of their award detailing the calculation and grant letters for those employees who elect to receive awards in stock options.

Generally, STAR awards are paid in cash. However, before the end of the calendar year preceding the award date, eligible participants can elect to receive their STAR award in forms other than cash. Alternatives to cash include stock options, stock appreciation rights ("SARs"), restricted stock units ("RSUs"), local deferral programs (depending on local regulations in some countries) and/or deferred compensation (for employees eligible to participate in the Executive Deferred Compensation Program). The number of stock options or SARs awarded to each employee will be determined on grant date by determining the USD value of the award chosen by the employee to be paid in stock options and dividing that value by the grant date GAAP expense of one stock option. The result will be rounded up to the nearest whole share. Any STAR award paid in stock options or other form of equity shall be awarded pursuant to this program and the terms and conditions of the 2019 Plan or any successor stock plan approved in accordance with applicable listing standards, as they may be revised from time to time. STAR awards paid in stock options or SARs will have the following terms unless otherwise approved by the C&LD Committee at grant:

Grant date will be the last business day on or before September 15. If the New York Stock Exchange is closed on the day of the grant, then the C&LD Committee will establish a grant date as soon as practical following the date previously specified. Provided participants remain in compliance with the terms and conditions set forth in the currently active Stock Plan and the Regulations, STAR stock options and SARs are not forfeitable, will become exercisable three years after the grant date, and will expire ten years after the grant date. In the event of death of the participant, the award becomes exercisable as of the date of death and the award remains exercisable until the Expiration Date. For awards granted in France or the United Kingdom, the consequences of death are determined by the local plan supplement, if applicable.

The option price used for any STAR Award will be the closing price for a share of Common Stock on the New York Stock Exchange on the grant date, or such higher price as may be specified in the French Addendum of the Regulations (the "Grant Price").

#### **IV. SEPARATION FROM THE COMPANY**

- **Retirement, Death or Special Separation Agreement:** If a participant worked at least 28 days (4 calendar weeks) during the fiscal year, the STAR award is pro-rated by dividing the number of calendar days the participant was an "active employee" during the fiscal year by 365.
- **Voluntary Resignation or Termination for cause:** Separating employees must have been active employees as of June 30 or the last business day in June (the close of the fiscal year for which the award is payable) to receive an award.

- 
- **Separation due to a Company authorized divestiture:** In the case of divestitures the CHRO is authorized to determine the appropriate STAR payout based on Business Unit factors either at Target or at projected or actual business results. The CHRO is also authorized to pay awards for the current or following partial fiscal year at time of divestiture close for administrative convenience.

Eligible participants who have left the Company will receive a cash payment (stock options can only be issued to active employees) on the same timing as STAR awards or as soon thereafter as possible.

#### **V. CHANGE IN CONTROL**

Notwithstanding the foregoing, if there is a Change in Control in any fiscal year, STAR awards will be calculated in accordance with Section II above, but each factor will be calculated for the period from the beginning of the fiscal year in which a Change in Control occurred up to and including the date of such Change in Control ("CIC Period"). "Change in Control" shall have the same meaning as defined in the 2019 Plan or any successor stock plan.

#### **VI. GENERAL TERMS AND CONDITIONS**

While any STAR award amount received by one individual for any year shall be considered as earned remuneration in addition to salary paid, it shall be understood that this plan does not give to any officer or employee any contract rights, express or implied, against any Company for any STAR

award or for compensation in addition to the salary paid to him or her, or any right to question the action of the Board of Directors or the C&LD or STAR Committees.


The Chief Human Resources Officer or the Chief Legal Officer may withhold a STAR award for a separated employee who is discovered to have engaged in serious misconduct or actions detrimental to the Company's interests. Each award to an individual at Band 7 and above, made pursuant to this plan, is subject to the Senior Executive Recoupment Policy as amended by the C&LD Committee in April 2018.

To the extent applicable, it is intended that STAR comply with the provisions of Section 409A. STAR will be administered and interpreted in a manner consistent with this intent. Neither a Participant nor any of a Participant's creditors or beneficiaries will have the right to subject any deferred compensation (within the meaning of Section 409A) payable under STAR to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment or garnishment. Except as permitted under Section 409A, any deferred compensation (within the meaning of Section 409A) payable to a Participant under STAR may not be reduced by, or offset against, any amount owing by a Participant to the Company.

This program document may be amended at any time by the C&LD Committee.

## Exhibit (10-2)

### Short Term Achievement Reward Program – related correspondence and terms and conditions



#### AWARD AGREEMENT

<NAME>

Subject: NON-STATUTORY STOCK OPTION SERIES STAR-XX

In recognition of your contributions to the future success of the business, The Procter & Gamble Company ("Company") hereby grants to you an option to purchase shares of Procter & Gamble Common Stock as follows:

Option Price per Share:  
Number of Shares:  
Grant Date:  
Expiration Date:  
Vest Date:

This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any applicable sub-plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), this Award Agreement including Attachments and the Exercise Instructions in place as may be revised from time to time. Notwithstanding the foregoing, Section 6.1(b) of the Plan (regarding non-compete obligations) shall not apply to this Award Agreement. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this hyperlink: [The Procter & Gamble 2019 Stock and Incentive Compensation Plan](#) and the Regulations and Sub Plans by activating this hyperlink: [Regulations of the Committee](#). If you have difficulty accessing the materials online, please send an email to [Execcomp.IM@pg.com](mailto:Execcomp.IM@pg.com) for assistance.



### **Vesting and Exercise**

As long as you remain in compliance with the terms of the Plan and the Regulations, this Award will not be forfeitable, will become exercisable on the Vest Date, and will expire on the Expiration Date. In the event of death, the Vest Date for this Award becomes your date of death and the Award remains exercisable until the Expiration Date.

This Award Agreement, including Attachment A, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company regarding this specific Award. Any legal action related to this Award, including Article 6 of the Plan (other than Section 6.1(b), which does not apply to this Award Agreement) must be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said courts solely for legal actions related to this Award.

You do not need to do anything further to accept this Award under the terms of the Plan. Attachment A is a copy of the Employee Acknowledgement and Consent Form that you completed when you elected to receive your STAR award in options.

THE PROCTER & GAMBLE COMPANY

### **Bala Purushothaman**

Chief Human Resources Officer

### **Attachment A**

Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions governing this Award.

### **Nature of the Award**

By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for any purposes including, but not limited to, calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment relationship with P&G; and furthermore, the Award will not be interpreted to form an employment contract with my employer ("Employer"); vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not create a right to further employment with my Employer and shall not interfere with the ability of my Employer to terminate my employment relationship at any time, with or without cause; ix) and no claim or entitlement to compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G and my Employer from any such claim that may arise.

### **Data Privacy**

I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this document by and among, as applicable, my Employer and The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive purpose of implementing, administering and managing my participation in the Plan.

I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside the European Economic Area), and that the recipient's country may have different data privacy laws and protections than my country. I understand that I may request a list with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

---

#### **Responsibility for Taxes**

Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related withholding ("Tax-Related Items"), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or the potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.

Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer to satisfy all withholding and payment on account obligations of P&G and/or my Employer. In this regard, I authorize P&G and/or my Employer to withhold all applicable Tax-Related Items from my wages or other cash compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items as described in this section.

## **Exhibit (10-3)**

### **The Procter & Gamble Performance Stock Program Summary**

---

#### **PERFORMANCE STOCK PROGRAM SUMMARY**

(Effective July 1, 2023)

The Performance Stock Program ("PSP") is a part of The Procter & Gamble Company's (the "Company") long-term incentive ("LTI") compensation and is designed to provide additional focus on key Company measures for top executives with senior management responsibility for total Company results. Awards granted under the PSP ("PSP Awards") are made pursuant to authority delegated to the Compensation & Leadership Development Committee (the "C&LD Committee") by the Board of Directors for determining compensation for the Company's principal officers and for making awards under the Procter & Gamble 2019 Stock and Incentive Compensation Plan (the "2019 Plan") or any successor stock plan approved in accordance with applicable listing standards.

#### **I. ELIGIBILITY**

The Chairman of the Board and/or Chief Executive Officer and those active executives at Band 6 or above as of June 1 prior to the grant date and recommended by management are eligible to participate ("Participants"). In special circumstances such as for acquisitions or experienced hires, the CHRO may authorize participation for Band 6 or above employees who are not active as of June 1 but are active employees as of the grant date.

## II. OVERVIEW

A significant portion of the Band 6 and above compensation is delivered through two long-term incentive programs tied to Company performance: PSP and the Long-term Incentive Program.

Total long-term incentive compensation targets are based on relevant competitive market data considering the median total long-term compensation of comparable positions, regressed for revenue size. The C&LD Committee establishes the Peer Group and sets compensation targets for all Principal Officers including the CEO. The CEO approves compensation targets for non-Principal Officers (generally Band 6 managers).

The C&LD Committee determines the long-term incentive award for the CEO. The CEO recommends all other Principal Officer awards to the C&LD Committee based on benchmarked long-term compensation targets, adjusted for business results and individual contributions attributable to each executive and including that individual's leadership skills. The C&LD Committee retains full authority to accept, modify, or reject these recommendations. The CEO approves awards for participants who are not Principal Officers based on long-term compensation targets, business results and individual contributions. Long-term incentive awards can be up to 50% above or 50% below the benchmarked target. In exceptional cases, no award will be made. After total LTI award size is determined then approximately half of each Band 7 manager's long-term compensation is allocated to PSP via an Initial PSU Grant (as defined below). The remaining portion is a Long-term Incentive Program Grant. Approximately 25% of each Band 6 manager's total LTI is allocated to PSP with the remainder awarded under the Long-term Incentive Program.

PSP rewards Participants for Company performance against certain three-year performance goals in categories established by the C&LD Committee. The C&LD Committee sets these performance goals for each three-year period that begins on July 1 and ends on June 30 three years later ("Performance Period"). In the first year of each Performance Period, the C&LD Committee grants Performance Stock Units ("PSUs") to Participants that will vest at the end of the Performance Period based on the Company's performance relative to the pre-established performance goals ("Initial PSU Grant"). The number of PSUs that vest at the end of the Performance Period depends on the Company's performance against the pre-established performance goals. Vested PSUs, including dividend equivalents, are converted into shares of the Company's common stock ("Common Stock") delivered to the applicable Participant within 60 days following the end of the Performance Period, or such later date as may be elected by the Participant in accordance with Section 409A of the Internal Revenue Code ("Section 409A").

## III. PERFORMANCE CATEGORIES

The PSP Award is based on the Company's performance in each of the following categories (each a "Performance Category") and weighted as indicated:

- Organic sales growth (percentile rank in the competitive peer group)\* – 30%
- Constant currency core before-tax operating profit growth – 20%
- Core earnings per share (EPS) growth – 30%
- Adjusted free cash flow productivity – 20%

Awards will be further adjusted based on the three-year relative total shareholder return (R-TSR) of P&G compared to the competitive peer group\*. Awards will be adjusted for top quartile performance using a 125% multiplier to increase awards, and reduced for bottom quartile performance using a 75% multiplier.

\* Competitive peer group is defined in the PSP Accounting Guidelines.

Within the first 90 days of each Performance Period, the C&LD Committee sets three-year performance goals ("Performance Goals") for each Performance Category for such Performance Period and establishes a sliding scale to measure the Company's performance against each Performance Goal in each Performance Category. The C&LD Committee uses the sliding scale to establish a payout factor between 0% and 200% for each Performance Category (a "Sales Factor", "Profit Factor", "EPS Factor" and "Cash Flow Factor", collectively, "Performance Factors"). The final aggregated payout factor (including the R-TSR multiplier) may not exceed 200%.

In all cases, the C&LD Committee retains the discretion to include or exclude certain of the Performance Categories for purposes of determining the PSP Award. The C&LD Committee may reduce or eliminate any payment if it determines that such payout is inconsistent with long-term shareholders' interests or incongruous with the overall performance of the company.

PSP awards will have the following terms unless otherwise approved by the C&LD Committee:

#### **IV. THE INITIAL PSU GRANT**

The C&LD Committee has the sole discretion to establish the target award ("PSP Target") for each Participant serving as a Principal Officer. The CEO establishes the PSP Targets for participants who are not Principal Officers. The PSP Target will be a cash amount and will be the basis for the Initial PSU Grant. The C&LD Committee will make the Initial PSU Grant on the first business day in October ("Grant Date") following the beginning of each Performance Period. If the New York Stock Exchange is closed on the day of the grant, then the C&LD will establish a grant date as soon as practical subsequent to the date previously specified for such award. The Initial PSU Grant will set forth a target and maximum number of PSUs. The target number of PSUs will be determined by dividing the PSP Target by the closing price ("Grant Price") of the Company's Common Stock on the New York Stock Exchange as of the close of business on the Grant Date, rounding to the nearest whole unit.

#### **V. PSU VESTING AND PAYMENT**

After the Performance Period is complete, the C&LD Committee will establish the Payout Factors for each of the Performance Categories based on the Company's results versus the pre-established Performance Goals. The number of PSUs that vest will be determined by multiplying the Performance Factors by their respective weightings, summing up the results, then applying the R-TSR multiplier if applicable. The final result will be rounded up or down to the nearest full percentage. The resulting percentage will be applied to the number of PSUs in the Initial PSU Grant target, including dividends that would have accumulated since the initial PSU grant on the vested units. Any resulting fractional share units may be paid as cash, fractional shares, or rounded up to the next full share based on administrative preference of the Company. The number of PSUs that vest may be equal to, above or below the Initial PSU Grant target depending on the Company's performance in the Performance Categories, but in no event more than the Initial PSU Grant maximum. Vested PSUs are converted into shares of Common Stock delivered to the applicable Participant within 60 days following the end of the Performance Period, or such later date as may be elected by the Participant if applicable and in accordance with Section 409A.

Participants at Band 7 and above may elect to defer delivery of the Common Stock by electing to receive Restricted Stock Units. PSP RSUs will have the following terms unless otherwise approved by the Committee at grant:

**VESTING AND SETTLEMENT:** PSP RSUs will be vested on the grant date with a settlement date at least one year following the original PSU delivery date (as elected by the Participant), are eligible for dividend equivalents, and can be further deferred in accordance with Section 409A. These RSUs will be paid on their Original Settlement Date or the Agreed Settlement Date, except in the case of death. In the case of death (except in France and the UK), payment will be made by the later of the end of the calendar year or two and a half months following the date of death. For awards granted in France or the UK, the consequences of death are determined by the local plan supplement, if applicable.

#### **VI. SEPARATION FROM THE COMPANY** (Defined terms shall have the meaning designated in the 2019 Plan or related award documents)

---

If the Participant's Termination of Employment occurs for any reason before the Vest Date then the Award will be forfeited unless one of the conditions listed below is met. If the Participant remains employed through the Vest Date, the Award will be paid on the Settlement Date. For the purposes of this Award, termination of employment will be effective as of the date the Participant is no longer actively employed and will not be extended by any notice period required under local law. Participants must remain in compliance with the terms and conditions set forth in the 2019 Plan, including those in Article 6.

**1. Termination on Account of Death.** In the event of death, the Award is not forfeited and will become deliverable on the Settlement Date or Agreed Settlement Date, whichever is applicable.

**2. Termination for a Qualified Reason Listed Below.** In the event the Participant terminates employment for one of the qualified reasons listed below, after the Grant Date but within four weeks, the Award will be forfeited. In the event of termination for one of the qualified reasons listed below, on or after four weeks following the Grant Date, but prior to September 30 of the following year, the award will be prorated based on the number of days the Participant remained an employee between the Grant Date and September 30 of the following year. If the termination for one of the qualified reasons listed below occurs after September 30 of the following year, the entire award will be retained. The portion of the award that is ultimately retained will be delivered on the Settlement Date in this Award Agreement as long as the Participant remain in compliance with the terms of the Plan and the Regulations. Qualified termination reasons are as follows:

- Retirement or Disability;
- Termination pursuant to a written separation agreement from the Company or a subsidiary that provides for equity retention; or
- Termination in connection with a divestiture or separation of any of the Company's businesses.

## **VII. CHANGE IN CONTROL**

Notwithstanding the foregoing, if there is a Change in Control that meets the requirements of a change in control event under Section 409A, all outstanding PSP Awards will vest and be paid according to Article 17 of the 2019 Stock Plan. If there is a Change in Control event that does not meet the requirements of a change in control event under Section 409A, all outstanding PSP Awards will be settled according to the terms and conditions set forth herein, without the application Article 17 of the 2019 Plan. "Change in Control" shall have the same meaning as defined in the 2019 Plan or any successor stock plan approved in accordance with applicable listing standards.

## **VIII. GENERAL TERMS AND CONDITIONS**

It shall be understood that the PSP does not give to any officer or employee any contract rights, express or implied, against any Company for any PSP Award, or for compensation in addition to the salary paid to him or her, or any right to question the action of the Board of Directors or the C&LD Committee.

Each PSP Award made to an individual at Band 7 and above is subject to the Senior Executive Recoupment Policy as adopted by the C&LD Committee.


---

To the extent applicable, it is intended that the PSP comply with the provisions of Section 409A. The PSP will be administered and interpreted in a manner consistent with this intent. Neither a Participant nor any of a Participant's creditors or beneficiaries will have the right to subject any deferred compensation (within the meaning of Section 409A) payable under the PSP to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment or garnishment. Except as permitted under Section 409A, any deferred compensation (within the meaning of Section 409A) payable to a Participant under the PSP may not be reduced by, or offset against, any amount owing by a Participant to the Company.

This program document may be amended at any time by the C&LD Committee.

Exhibit (10-4)

Performance Stock Program related correspondence and terms and conditions



Subject: PERFORMANCE STOCK UNIT SERIES

In recognition of your contributions to the future success of the business, The Procter & Gamble Company ("Company") hereby grants to you Performance Stock Units ("PSUs") of Procter & Gamble Common Stock as follows:

Target Number of Units:	
Maximum Payout Percentage:	200%
Conversion Ratio:	1 PSU = 1 Common Share
Grant Date:	
Vest Date:	
Performance Period:	1-July-2023 to 30-June-2026
Original Settlement Date (Shares Delivered on):	18-August-2026
Acceptance Deadline:	

This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any applicable sub-plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), and this Award Agreement, including Attachments A and B. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this hyperlink: [The Procter & Gamble 2019 Stock and Incentive Compensation Plan](#) and the Regulations and Sub Plans by activating this hyperlink: [Regulations of the Committee](#). If you have difficulty accessing the materials online, please send an email to [Execcomp.IM@pg.com](mailto:Execcomp.IM@pg.com) for assistance.

Voting Rights and Dividend Equivalents

As a holder of PSUs, during the period from the Grant Date until the date the PSUs are paid, each time a cash dividend or other cash distribution is paid with respect to Common Stock, you will receive additional PSUs ("Dividend Equivalent PSUs"). The number of Dividend Equivalent PSUs will be determined as follows: multiply the number of PSUs and Dividend Equivalent PSUs currently held by the per share amount of the cash dividend or other cash distribution on Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution. These Dividend Equivalent PSUs will be subject to the same terms and conditions as the original PSUs that gave rise to them, including performance vesting and settlement terms, except that if there is a fractional number of Dividend Equivalent PSUs on the date the PSUs are paid, the resulting fractional share units may be paid as cash, fractional shares, or rounded up to the nearest full share based on administrative preference of the Company. This Award represents an unfunded, unsecured right to receive payment in the future, and does not entitle you to voting rights or dividend rights as a shareholder.

Performance Vesting

1. Your Target Number of Units indicated in this Award Agreement (the "Target Units") will vest depending upon performance during the Performance Period, as specified below. This Award Agreement also sets forth the

---

Maximum Payout Percentage that you may receive pursuant to this Award. Your right to receive all, any portion of, or more than the Target Units (but in no event more than the Maximum Payout Percentage) will be contingent upon the achievement of specified levels of certain performance goals measured over the Performance Period. The applicable performance goals and the payout factors for each performance goal applicable to your Award for the Performance Period are set forth in the PSP Performance and Payout Factors attachment.

2. Within 60 days following the end of the Performance Period, the Committee will determine (i) whether and to what extent the performance goals have been satisfied for the Performance Period, (ii) the number of PSUs that shall become deliverable under this Award, and (iii) whether the other applicable conditions for receipt of shares of Common Stock in respect of the PSUs have been met. Any PSUs not approved by the Committee in accordance with this paragraph will be forfeited and cancelled.

#### **Vesting and Payment**

**If you leave the Company before the Vest Date, the Award will be forfeited unless you meet one of the conditions listed below.** If you remain employed through the Vest Date, the Award will be paid on the Original Settlement Date or Agreed Settlement Date (as defined below). For the purposes of this Award, termination of employment will be effective as of the date that you are no longer actively employed and will not be extended by any notice period required under local law.

**1. Termination on Account of Death.** In the event of death, the Award is not forfeited and will become deliverable on the Settlement Date or Agreed Settlement Date, whichever is applicable.

**2. Termination for a Qualified Reason Listed Below.** In the event you terminate employment for one of the qualified reasons listed below, after the Grant Date but before the four-week anniversary of the Grant Date, the Award will be forfeited. In the event of termination for one of the qualified reasons listed below, on or after the four-week anniversary of the Grant Date, but prior to the one-year anniversary of the Grant Date, the award will be prorated based on the number of days you remained an employee between the Grant Date and the one-year anniversary of the Grant Date. If the termination for one of the qualified reasons listed below occurs after the one-year anniversary of the Grant Date, the entire award will be retained. The portion of the award that is ultimately retained will be delivered on the Original Settlement Date or Agreed Settlement Date, whichever is applicable, as long as you remain in compliance with the terms of the Plan and the Regulations. Qualified termination reasons are as follows:

- Retirement or Disability;
- Termination pursuant to a written separation agreement from the Company or a subsidiary that provides for equity retention; or
- Termination in connection with a divestiture or separation of any of the Company's businesses.

Notwithstanding the foregoing, in the event of a Change in Control, the Target Number of Units shall be paid pursuant to the terms provided in the Plan.

Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to the Plan, subject to applicable tax withholding.

#### **Deferral Election (Applicable to participants Band 7 and above as of the Award Date)**

At any time at least six months prior to the end of the Performance Period and so long as the achievement of the applicable performance goals are not yet readily ascertainable (but in no event later than your Termination of Employment from the Company), you and the Company may agree to postpone the Original Settlement Date to such later date ("Agreed Settlement Date") as may be elected by you, which date shall be at least five years later than the Original Settlement Date and in accordance with Internal Revenue Code Section 409A.

This Award Agreement including Attachment A, the PSP Performance and Payout Factors, and the Stock Plan and Regulations of the Committee together constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements that have been entered by you with the Company regarding this specific Award. Unless otherwise required by local law, any legal action related to this Award, including Article 6 of the Plan, may be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said courts solely for legal actions related to this Award. You have the right to consult with a lawyer before accepting this Award.

---



**Bala Purushothaman**  
Chief Human Resources Officer

**IMPORTANT**

By accepting this award within your E\*TRADE account, you agree to be bound by the following:

1. [The Procter & Gamble 2019 Stock Plan](#) including the non-compete and non-solicitation clauses,
2. the [Stock Plan Regulations of the Committee](#),
3. This Award Agreement including Attachment A (at end of this document),
4. any additional terms and conditions relevant to your current home and/or host market listed on the following page,
5. and the attached PSP Performance Factors and Payout Formula.

**Market Supplemental Information**

Please review the following table for disclosures required for your home and/or host market. All Market Supplemental documents are links to the actual documents.

Home Market	Host Market	Document Name
US	US	<a href="#">U.S. Non-Compete Addendum</a>
Any	Canada	<a href="#">PG Annual Report</a>
Any	Belgium, Croatia, Denmark, Luxembourg, Poland, United Kingdom	<a href="#">Appendix of Market Specific Terms and Conditions</a> <a href="#">European Union Prospectus</a>
Any	Algeria, Argentina, Australia, Azerbaijan, Bangladesh, Bosnia & Herzegovina, Canada, Chile, China, Hong Kong, Indonesia, Kenya, Mexico, Morocco, Pakistan, Russia, Saudi Arabia, Senegal, Singapore, South Korea, South Africa, Sri Lanka, Ukraine, United Arab Emirates, Vietnam	<a href="#">Appendix of Market Specific Terms and Conditions</a>
Any	Austria, Bulgaria, Czech Republic, Estonia, Finland, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Romania, Slovakia, Slovenia, Spain, Sweden	<a href="#">European Union Prospectus</a>
Not US	All except US	<a href="#">Estate Tax Treatment</a>
Any	Denmark	<a href="#">Denmark Supplemental Information</a>
	Switzerland (Home or Host)	<a href="#">Swiss Tax Treatment</a>

---

## Attachment A

Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions governing this Award.

### Nature of the Award

By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for any purposes including, but not limited to, calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment relationship with P&G; and furthermore, the Award will not be interpreted to form an employment contract with my employer ("Employer"); vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not create a right to further employment with my Employer and shall not interfere with the ability of my Employer to terminate my employment relationship at any time, with or without cause; ix) and no claim or entitlement to compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G and my Employer from any such claim that may arise.

### Data Privacy

I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this document by and among, as applicable, my Employer and The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive purpose of implementing, administering and managing my participation in the Plan.

I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside the European Economic Area), and that the recipient's country may have different data privacy laws and protections than my country. I understand that I may request a list with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

---

### Responsibility for Taxes


Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related withholding ("Tax-Related Items"), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or the potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.

Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer to satisfy all withholding and payment on account obligations of P&G and/or my Employer. In this regard, I authorize P&G and/or my Employer to withhold all applicable Tax-Related Items from my wages or other cash compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items as described in this section.

## Exhibit (10-5)

### Long-Term Incentive Program related correspondence and terms and conditions

---

 0000080424-23-000103imagea.jpg

#### FORM NSO - AWARD AGREEMENT

Subject: NON-STATUTORY STOCK OPTION SERIE

In recognition of your contributions to the future success of the business, The Procter & Gamble Company ("Company") hereby grants to you an option to purchase shares of Procter & Gamble Common Stock as follows:

Option Price per Share:

Number of Shares:

Grant Date:

Expiration Date:

Vest Date:

Acceptance Deadline:

This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any applicable sub-plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), this Award Agreement including Attachments and the Exercise Instructions in place as may be revised from time to time. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this hyperlink: [The Procter & Gamble 2019 Stock and Incentive Compensation Plan and the Regulations and Sub Plans](#) by activating this hyperlink: [Regulations of the Committee](#). If you have difficulty accessing the materials online, please send an email to [Execcomp.IM@pg.com](mailto:Execcomp.IM@pg.com) for assistance.

#### Vesting and Exercise

If you leave the Company before the Vest Date, the Award will be forfeited unless you meet one of the conditions listed below. If you remain employed through the Vest Date, the Award will become exercisable on the Vest Date. If you terminate employment before the Expiration Date and prior to exercising the Award, except for the reasons listed below, the Award will be forfeited immediately upon your termination of employment. For the purposes of this Award, termination of employment will be effective as of the date that you are no longer actively employed and will not be extended by any notice period required under local law.

**1. Termination on Account of Death.** In the event of death, the Vest Date for this Award becomes your date of death and the Award in its entirety remains exercisable until the Expiration Date.

**2. Termination for a Qualified Reason Listed Below.** In the event you terminate employment for one of the qualified reasons listed below, after the Grant Date but before the four-week anniversary of the Grant Date, the Award will be forfeited. In the event of termination for one of the qualified reasons listed below, on or after the four-week anniversary of the Grant Date, but prior to the one-year anniversary of the Grant Date, the award will be prorated based on the number of days you remained an employee between the Grant Date and the one-year anniversary of the Grant Date. If the termination for one of the qualified reasons listed below occurs after the one-year anniversary of the Grant Date, the entire award will be retained. The portion of the award that is ultimately retained will be exercisable on the Vest Date in this Award Agreement and will expire on the Expiration Date as long as you remain in compliance with the terms of the Plan and the Regulations. Qualified termination reasons are as follows:

- Retirement or Disability;


- Termination pursuant to a written separation agreement from the Company or a subsidiary that provides for equity retention; or
- Termination in connection with a divestiture or separation of any of the Company's businesses.

This Award Agreement, including Attachment A, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company regarding this specific Award. Unless otherwise required by local law, any legal action related to this Award, including Article 6 of the Plan, must be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said courts solely for legal actions related to this Award. You have the right to consult with a lawyer before accepting this Award.

THE PROCTER & GAMBLE COMPANY  
Bala Purushothaman  
Chief Human Resources Officer

#### IMPORTANT

By accepting this award within your E\*TRADE account, you agree to be bound by The Procter & Gamble 2019 Stock Plan including the non-compete and non-solicitation clauses, the Stock Plan Regulations of the Committee, this Award Agreement including Attachment A (at end of this document), and any additional terms and conditions relevant to your current home and/or host market listed on the following page.



#### FORM RSU - AWARD AGREEMENT

Subject: RESTRICTED STOCK UNIT SERIES

%%GRANT\_USER\_DEFINED\_FIELD\_2%-%%

In recognition of your contributions to the future success of the business, The Procter & Gamble Company ("Company") hereby grants to you Restricted Stock Units ("RSUs") of Procter & Gamble Common Stock as follows:

Number of Restricted Stock Units:

Grant Date Share Price:

Grant Date:

Vest Date:

Settlement Date (Shares Delivered on):

Acceptance Deadline:

This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any applicable sub-plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), this Award Agreement including Attachments and the Settlement Instructions in place as may be revised from time to time. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this hyperlink: [The Procter & Gamble 2019 Stock and Incentive Compensation Plan](#) and the Regulations and Sub Plans by activating this hyperlink: [Regulations of the Committee](#). If you have difficulty accessing the materials online, please send an email to [Execcomp.IM@pg.com](mailto:Execcomp.IM@pg.com) for assistance.

#### **Voting Rights and Dividend Equivalents**

As a holder of RSUs, during the period from the Grant Date until the date the RSUs are paid, each time a cash dividend or other cash distribution is paid with respect to Common Stock, you will receive additional RSUs ("Dividend Equivalent RSUs"). The number of Dividend Equivalent RSUs will be determined as follows: multiply the number of RSUs and Dividend Equivalent RSUs currently held by the per share amount of the cash dividend or other cash distribution on Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution. These Dividend Equivalent RSUs will be subject to the same terms and conditions as the original RSUs that gave rise to them, including vesting and settlement terms, except that if there is a fractional number of Dividend Equivalent RSUs on the date the RSUs are paid, the resulting fractional share unit may be paid as cash, fractional shares, or rounded up to the nearest full share based on administrative preference of the Company. This Award represents an unfunded, unsecured right to receive payment in the future, and does not entitle you to voting rights or dividend rights as a shareholder.

#### **Vesting and Payment**

If you leave the Company before the Vest Date, the Award will be forfeited unless you meet one of the conditions listed below. If you remain employed through the Vest Date, the Award will be paid on the Settlement Date. For the purposes of this Award, termination of employment will be effective as of the date that you are no longer actively employed and will not be extended by any notice period required under local law.

**1. Termination on Account of Death.** In the event of death, the Award will be immediately and fully vested and payment will be made by the later of the end of the calendar year or two and a half months following the date of death.

**2. Termination for a Qualified Reason Listed Below.** In the event you terminate employment for one of the qualified reasons listed below, after the Grant Date but before the four-week anniversary of the Grant Date, the Award will be forfeited. In the event of termination for one of the qualified reasons listed below, on or after the four-week anniversary of the Grant Date, but prior to the one-year anniversary of the Grant Date, the award will be prorated based on the number of days you remained an employee between the Grant Date and the one-year anniversary of the Grant Date. If the termination for one of the qualified reasons listed below occurs after the one-year anniversary of the Grant Date, the entire award will be retained. The portion of the award that is ultimately retained will be delivered on the Settlement Date in this Award Agreement as long as you remain in compliance with the terms of the Plan and the Regulations. Qualified termination reasons are as follows:

- Retirement or Disability;
- Termination pursuant to a written separation agreement from the Company or a subsidiary that provides for equity retention; or
- Termination in connection with a divestiture or separation of any of the Company's businesses.

Notwithstanding the foregoing, in the event of a Change in Control, payment shall be made pursuant to the terms provided in the Plan.

Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to the Plan, subject to applicable tax withholding.

This Award Agreement, including Attachment A, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company regarding this specific Award. Unless otherwise required by local law, any legal action related to this Award, including Article 6 of the Plan, must be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said courts solely for legal actions related to this Award. You have the right to consult with a lawyer before accepting this Award.

THE PROCTER & GAMBLE COMPANY

**Bala Purushothaman**

Chief Human Resources Officer

**IMPORTANT**

By accepting this award within your E\*TRADE account, you agree to be bound by The Procter & Gamble 2019 Stock Plan including the non-compete and non-solicitation clauses, the Stock Plan Regulations of the Committee, this Award Agreement including Attachment A (at end of this document), and any additional terms and conditions relevant to your current home and/or host market listed on the following page.

**Market Supplemental Information**

Please review the following table for disclosures required for your home and/or host market. All Market Supplemental documents are links to the actual documents.

Home Market	Host Market	Document Name
US	US	<a href="#">U.S. Non-Compete Addendum</a>
Any	Canada	<a href="#">PG Annual Report</a>
Any	Belgium, Croatia, Denmark, Luxembourg, Poland, United Kingdom	<a href="#">Appendix of Market Specific Terms and Conditions</a> <a href="#">European Union Prospectus</a>
Any	Algeria, Argentina, Australia, Azerbaijan, Bangladesh, Bosnia & Herzegovina, Canada, Chile, China, Hong Kong, Indonesia, Kenya, Mexico, Morocco, Pakistan, Russia, Saudi Arabia, Senegal, Singapore, South Korea, South Africa, Sri Lanka, Ukraine, United Arab Emirates, Vietnam	<a href="#">Appendix of Market Specific Terms and Conditions</a>
Any	Austria, Bulgaria, Czech Republic, Estonia, Finland, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Romania, Slovakia, Slovenia, Spain, Sweden	<a href="#">European Union Prospectus</a>
Not US	All except US	<a href="#">Estate Tax Treatment</a>
Any	Denmark	<a href="#">Denmark Supplemental Information</a>
	Switzerland (Home or Host)	<a href="#">Swiss Tax Treatment</a>

**Attachment A**

Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions governing this Award.

### **Nature of the Award**

By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for any purposes including, but not limited to, calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment relationship with P&G; and furthermore, the Award will not be interpreted to form an employment contract with my employer ("Employer"); vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not create a right to further employment with my Employer and shall not interfere with the ability of my Employer to terminate my employment relationship at any time, with or without cause; ix) and no claim or entitlement to compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G and my Employer from any such claim that may arise.

### **Data Privacy**

I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this document by and among, as applicable, my Employer and The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive purpose of implementing, administering and managing my participation in the Plan.

I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in my market or elsewhere (including countries outside the European Economic Area), and that the recipient's market may have different data privacy laws and protections than my market. I understand that I may request a list with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

### **Responsibility for Taxes**

Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related withholding ("Tax-Related Items"), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or the potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.

Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer to satisfy all withholding and payment on account obligations of P&G and/or my Employer. In this regard, I authorize P&G and/or my Employer to withhold all applicable Tax-Related Items from my wages or other cash compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items as described in this section.



## Exhibit (10-6)

# The Procter & Gamble 2019 Stock and Incentive Compensation Plan – Additional terms and conditions

0000080424-23-000103image1.jpg

### FORM BOD AWARD AGREEMENT

Subject: Award of Restricted Stock Units

This is to advise you that The Procter & Gamble Company ("Company") hereby grants to you Restricted Stock Units ("RSUs") of Procter & Gamble Common Stock as follows:

Number of Restricted Stock Units:

Grant Date Share Price:

Grant Date:

Vest Date:

Original Settlement Date:

One Year Following Termination of Directorship

This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any applicable sub-plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), and this Award Agreement, including Attachment A-BOD. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan.

#### Voting Rights and Dividend Equivalents

As a holder of RSUs, during the period from the Grant Date until the date the RSUs are paid, each time a cash dividend or other cash distribution is paid with respect to Common Stock, you will receive additional RSUs ("Dividend Equivalent RSUs"). The number of Dividend Equivalent RSUs will be determined as follows: multiply the number of RSUs and Dividend Equivalent RSUs currently held by the per share amount of the cash dividend or other cash distribution on Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution. These Dividend Equivalent RSUs will be subject to the same terms and conditions as the original RSUs that gave rise to them, including vesting and settlement terms, except that if there is a fractional number of Dividend Equivalent RSUs on the date the RSUs are paid, the resulting fractional share units may be paid as cash, fractional shares, or rounded up to the nearest full share based on administrative preference of the Company. This Award represents an unfunded, unsecured right to receive payment in the future, and does not entitle you to voting rights or dividend rights as a shareholder.

#### Vesting and Payment

If you remain a Non-Employee Director through the Vest Date, the Award will be paid on the Original Settlement Date or Agreed Settlement Date, whichever is applicable, except in the case of death or Disability. In the case of death or Disability, the Award will be fully vested and payment will be made by the later of the end of the calendar year or two and a half months following the date of death or Disability, as applicable. If you resign before the Vest Date for reasons of antitrust laws, or the Company's conflict of interest, corporate governance, or continued service policies, you will retain your Award subject to the terms and conditions governing the Award.

Notwithstanding the foregoing, in the event of a Change in Control, payment shall be made pursuant to the terms provided in the Plan.

Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to the Plan, subject to applicable tax withholding.

#### Deferral Election

At any time prior to Termination of Directorship, you and the Company may agree to postpone the Original Settlement Date to such later date ("Agreed Settlement Date") as may be elected by you, which date shall be at least five years later than the Original Settlement Date and in accordance with Internal Revenue Code Section 409A.

This Award Agreement including Attachment A-BOD, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understanding and/or agreements that have been entered by you with the Company regarding this specific Award. Unless otherwise required by local law, any legal action related to this Award may be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said courts solely for legal actions related to this Award.

THE PROCTER & GAMBLE COMPANY

**Bala Purushothaman**

Chief Human Resources Officer

#### **Attachment A-BOD**

Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions governing this Award.

#### **Nature of the Award**

By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation for any purposes including, but not limited to, calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) the Award will not be interpreted to form an employment relationship with P&G; and furthermore, the Award will not be interpreted to form an employment contract with P&G; vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not interfere with the ability of P&G to terminate my directorship at any time, with or without cause; ix) and no claim or entitlement to compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G from any such claim that may arise.

#### **Data Privacy**


I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this document by and among, as applicable, The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive purpose of implementing, administering and managing my participation in the Plan.

I understand that P&G holds certain personal information about me, including, but not limited to, my name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, , any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside the European Economic Area), and that the recipient's country may have different data privacy laws and protections than my country. I understand that I may request a list with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

#### **Responsibility for Taxes**

Regardless of any action P&G takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related withholding ("Tax-Related Items"), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G (1) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or the potential impact of current or future tax legislation in any jurisdiction; and (2) does not commit to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.

Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G to satisfy all withholding and payment on account obligations of P&G. In this regard, I authorize P&G to withhold all applicable Tax-Related Items from my wages or other cash compensation paid to me by P&G or from proceeds of the sale of the shares. Alternatively, or in addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G any amount of Tax-Related Items that P&G may be required to withhold as a result of my participation in the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items as described in this section.



Subject: **RESTRICTED STOCK UNIT SERIES RTN2**

In recognition of your contributions to the future success of the business, The Procter & Gamble Company ("Company") hereby grants to you Restricted Stock Units ("RSUs") of Procter & Gamble Common Stock as follows:

Grant Date:	
Grant Date Share Price:	
Number of Restricted Stock Units:	
Vest Date:	
Settlement Date	See Payment and Vesting Details
Number of Restricted Stock Units:	
Vest Date:	
Settlement Date	See Payment and Vesting Details
Total Number of Restricted Stock Units:	

This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any applicable sub- plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), this Award Agreement including Attachments, and the Settlement Instructions in place as may be revised from time to time. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this hyperlink: The Procter & Gamble 2019 Stock and Incentive Compensation Plan and the Regulations and Sub Plans by activating this hyperlink: Regulations of the Committee. If you have difficulty accessing the materials online, please send an email to Execcomp.IM@pg.com for assistance.

**Voting Rights and Dividend Equivalents**

As a holder of RSUs, during the period from the Grant Date until the date the RSUs are paid, each time a cash dividend or other cash distribution is paid with respect to Common Stock, you will receive additional RSUs ("Dividend Equivalent RSUs"). The number of Dividend Equivalent RSUs will be determined as follows: multiply the number of RSUs and Dividend Equivalent RSUs currently held by the per share amount of the cash dividend or other cash distribution on Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution. These Dividend Equivalent RSUs will be subject to the same terms and conditions as the original RSUs that gave rise to them, including vesting and settlement terms, except that if there is a fractional number of Dividend Equivalent RSUs on the date the RSUs are paid, the resulting fractional share unit may be paid as cash, fractional shares, or rounded up to the nearest full share based on administrative preference of the Company. This Award represents an unfunded, unsecured right to receive payment in the future, and does not entitle you to voting rights or dividend rights as a shareholder.

**Payment and Vesting**

If you remain employed through the Vest Dates, the Award will be paid on the Vest Date(s) according to the vesting schedule except if you are a Board- Designated Section 16 Officer of the Company on the Vest Date(s) and in the case of death, as described below. If your Termination of Employment occurs for any reason before a Vest Date except for the reasons listed below, the Award will be forfeited. For the purposes of this Award, Termination of Employment will be effective as of the date that you are no longer actively employed and will not be extended by any notice period required under local law.

1. **Termination on Account of Death or Disability.** In the case of death or disability, the Award will be fully vested and payment will be made by the later of the end of the calendar year or two and a half months following the date of death or disability.
2. **Termination without Cause Pursuant to a Written Separation Agreement.** In the event of your Termination of Employment from the Company or a Subsidiary without Cause, your Award is forfeited unless you have executed a written separation agreement with the Company that provides for retention of this Award in which case the Award will be delivered on the Vest Date(s) as long as you remain in compliance with the terms of the Plan, the Regulations, and your separation agreement.
3. **Vesting for Board- Designated Section 16 Officers.** Payment will be on the Vest Date(s) except when the Vest Date(s) is outside of an open trading window as designated by the Company in accordance with the Company's Insider Trading Policy and the Section 16 Officer does not have a valid 10b5-1 plan in place instructing the sale of Common Stock to cover taxes and administrative costs, in which case payment will be made on the first day of the first such open trading window following the Vest Date(s).

Notwithstanding the foregoing, in the event of a Change in Control, payments shall be made pursuant to the terms provided in the Plan.

Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to the Plan, subject to applicable tax withholding.

This Award Agreement, including Attachment A, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company regarding this specific Award. Any legal action related to this Award, including Article 6 of the Plan, must be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said courts solely for legal actions related to this Award. You have the right to consult with a lawyer before accepting this Award.

THE PROCTER & GAMBLE COMPANY

**Bala Purushothaman**  
Chief Human Resources Officer

#### IMPORTANT

By accepting this award within your E\*TRADE account, you agree to be bound by [The Procter & Gamble 2019 Stock Plan](#) including the non-compete and non-solicitation clauses, the [Stock Plan Regulations of the Committee](#) and this Award Agreement including Attachment A (at end of this document).

#### Attachment A

Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions governing this Award.

#### Nature of the Award

By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for any purposes including, but not limited to, calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment relationship with P&G; and furthermore, the Award will not be interpreted to form an employment contract with my employer ("Employer"); vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not create a right to further employment with my employer and shall not interfere with the ability of my employer to terminate my employment relationship at any time, with or without cause; ix) and no claim or entitlement to compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G and my employer from any such claim that may arise.

#### Data Privacy

I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this document by and among, as applicable, my Employer and The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive purpose of implementing, administering and managing my participation in the Plan.

I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside the European Economic Area), and that the recipient's country may have different data privacy laws and protections than my country. I understand that I may request a list with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

#### **Responsibility for Taxes**

Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax- related withholding ("Tax- Related Items"), I acknowledge that the ultimate liability for all Tax- Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or undertakings regarding the treatment of any Tax- Related Items in connection with any aspect of this Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or the potential impact of current or future tax legislation in any

---

jurisdiction; and (2) do not commit to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.

Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer to satisfy all withholding and payment on account obligations of P&G and/or my employer. In this regard, I authorize P&G and/or my Employer to withhold all applicable Tax- Related Items from my wages or other cash compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax- Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount of Tax- Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax- Related Items as described in this section.

#### **EXHIBIT 31.1**

##### **Rule 13a-14(a)/15d-14(a) Certifications**

I, Jon R. Moeller, certify that:

- (1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- (4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

- c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- (5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ JON R. MOELLER

(Jon R. Moeller)

Chairman of the Board, President and Chief Executive Officer

October 18, 2023 January 23, 2024

Date

## EXHIBIT 31.2

### Rule 13a-14(a)/15d-14(a) Certifications

I, Andre Schulten, certify that:

- (1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- (4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- (5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ ANDRE SCHULTEN

(Andre Schulten)

Chief Financial Officer

October 18, 2023 January 23, 2024

Date

#### EXHIBIT 32.1

##### Section 1350 Certifications

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble Company (the "Company") certifies to his knowledge that:

- (1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2023 December 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the Company.

/s/ JON R. MOELLER

(Jon R. Moeller)

Chairman of the Board, President and Chief Executive Officer

October 18, 2023 January 23, 2024

Date

A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter & Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

#### EXHIBIT 32.2

##### Section 1350 Certifications

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble Company (the "Company") certifies to his knowledge that:

- (1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2023 December 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the Company.

/s/ ANDRE SCHULTEN

(Andre Schulten)

Chief Financial Officer

October 18, 2023 January 23, 2024

Date

A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter & Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.





#### DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.